[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 341
1. Foo CC, Lee JS, Guilanno V, Yan X, Tan SH, Giam YC: Squamous cell carcinoma and Bowen's disease of the skin in Singapore. Ann Acad Med Singapore; 2007 Mar;36(3):189-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma and Bowen's disease of the skin in Singapore.
  • INTRODUCTION: Non-melanoma skin cancer is one of the commonest cancers in Singapore and worldwide.
  • The aim of our study was to evaluate the demographic and clinicopathological patterns of squamous cell carcinoma (SCC) and Bowen's disease (BD) of the skin, in order to better understand the characteristics of these tumours in our population.
  • MATERIALS AND METHODS: Histologically proven cases of SCC and BD seen at our centre between 2002 and 2003 were retrospectively analysed according to age, sex, race, predisposing factors such as immunosuppression and ultraviolet therapy, site and size of tumour, histological differentiation and subtype, and treatment method.
  • RESULTS: A total of 161 patients were studied--81 with SCC, 68 with BD, and 12 with both tumours.
  • There were 199 tumours in total--105 SCC and 94 BD.
  • For both SCC and BD, males outnumbered females (ratio of 2.4:1 and 1.5:1 respectively); patient age averaged 72.9 years and 66.8 years respectively; and Chinese were the majority race.
  • The mean duration to presentation was 21.2 months for SCC compared with 39.9 months for BD, and common symptoms were itch, pain and bleeding for both.
  • CONCLUSIONS: SCC and BD show rather similar patient characteristics, with a predominance among males, having a predilection for the head and neck region, and with a tendency towards slow growth.
  • As incidences increase worldwide, it is important for healthcare providers to be adept at recognising and managing nonmelanoma skin cancers.
  • [MeSH-major] Bowen's Disease / epidemiology. Carcinoma, Squamous Cell / epidemiology. Skin Neoplasms / epidemiology


2. Grizzle WE, Srivastava S, Manne U: The biology of incipient, pre-invasive or intraepithelial neoplasia. Cancer Biomark; 2010;9(1-6):21-39
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For some organs, such as the oral cavity, cervix and skin, the respective putative pre-invasive lesions can be observed over time and documented to progress to invasive lesions.
  • 1) microinvasive disease developing from a pre-invasive neoplastic lesion, 2) the general association of the pre-invasive lesion with invasive lesions, 3) the subsequent development of invasive lesions following diagnosis of the pre-invasive lesion, 4) correlations of the molecular features of the putative pre-invasive lesion with the matching invasive lesions, and 5) reductions in the rate of cancer following removal of the pre-invasive lesion.
  • Less descriptive terms such as the degrees of dysplasia of the oral cavity and bronchopulmonary system and actinic keratosis and Bowen's disease of the skin might be better designated as oral intraepithelial neoplasia (OIN), pulmonary intraepithelial neoplasia (PulIN) and dermal intraepithelial neoplasia (DIN).
  • An excellent example of this is ulcerative colitis (UC) in which dysregulation of microsatellite repair enzymes have been documented one year following diagnosis of UC.
  • While the nomenclature, description, diagnosis and etiology of pre-invasive neoplasia has advanced, approaches to therapy of such lesions have not progressed adequately even though it has been identified that, for example, removal of polyps periodically from the colorectum, DCIS from the breast, and high grade CIN from the cervix, results in a reduction in the development of cancers of the colorectum, breast, and cervix, respectively.
  • [MeSH-major] Carcinoma in Situ / etiology
  • [MeSH-minor] Animals. Carcinoma, Adenosquamous / etiology. Carcinoma, Squamous Cell / etiology. Cell Transformation, Neoplastic / chemically induced. Cell Transformation, Neoplastic / radiation effects. Disease Progression. Environmental Exposure. Humans. Immunologic Surveillance. Metagenome. Mice. Neoplasm Regression, Spontaneous. Neoplasms, Experimental / etiology. Neoplastic Stem Cells / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biochem Suppl. 1994;19:259-66 [7823598.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):751-8 [6275978.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4264-7 [7671233.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1237-40 [8640805.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1197-200 [8630897.001]
  • [Cites] Eur Urol. 1996;30(2):153-66 [8875196.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14025-9 [8943054.001]
  • [Cites] J Histochem Cytochem. 2008 Mar;56(3):305-12 [18071066.001]
  • [Cites] Science. 2008 Feb 22;319(5866):1096-100 [18202256.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2813-20 [18539959.001]
  • [Cites] Pathobiology. 2008;75(2):75-84 [18544962.001]
  • [Cites] Science. 2008 Sep 5;321(5894):1361-5 [18703712.001]
  • [Cites] JAMA. 2008 Oct 1;300(13):1523-31 [18827209.001]
  • [Cites] N Engl J Med. 1985 Jan 17;312(3):146-51 [3965932.001]
  • [Cites] Hum Pathol. 1986 Jan;17(1):64-71 [3943853.001]
  • [Cites] Arch Pathol Lab Med. 1986 Nov;110(11):1076-9 [3778125.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):788-94 [2433020.001]
  • [Cites] Carcinogenesis. 1990 Aug;11(8):1393-8 [2167183.001]
  • [Cites] Hum Pathol. 1991 Jul;22(7):644-52 [1712748.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10124-8 [1946433.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1621-6 [10362784.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1825-30 [10362807.001]
  • [Cites] Head Neck. 1999 Sep;21(6):566-73 [10449674.001]
  • [Cites] Jpn J Cancer Res. 1999 Jul;90(7):711-9 [10470282.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1375-85 [16424164.001]
  • [Cites] Lab Invest. 2006 Feb;86(2):175-90 [16402033.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R897-908 [16280039.001]
  • [Cites] Nat Med. 2006 Aug;12(8):875-8 [16892025.001]
  • [Cites] Blood. 2007 May 15;109(10):4336-42 [17244679.001]
  • [Cites] J Immunol. 2007 Jun 1;178(11):6867-75 [17513735.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13732-7 [17702869.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8121-30 [17804724.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3407-16 [17666570.001]
  • [Cites] Nat Med. 1997 May;3(5):510-4 [9142118.001]
  • [Cites] Biotech Histochem. 1997 Mar;72(2):96-104 [9152522.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Jul;19(3):170-5 [9218998.001]
  • [Cites] J Natl Cancer Inst. 1998 Apr 1;90(7):523-31 [9539248.001]
  • [Cites] Oncol Rep. 1999 May-Jun;6(3):597-9 [10203598.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):298-310 [8454275.001]
  • [Cites] J Invest Dermatol. 1993 Jun;100(6):746-8 [8496613.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):558-61 [8505985.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] N Engl J Med. 1994 Jan 20;330(3):159-64 [8264737.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):765-78 [8037290.001]
  • [Cites] J Immunol. 2008 Oct 15;181(8):5242-8 [18832678.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] Breast Dis. 2008;29:27-36 [19029622.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):678-86 [19147584.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1302-13 [19190339.001]
  • [Cites] Nat Rev Immunol. 2009 Mar;9(3):162-74 [19197294.001]
  • [Cites] Int J Cancer. 2009 Jun 1;124(11):2621-33 [19235923.001]
  • [Cites] Cancer Biomark. 2010;9(1-6):41-64 [22112469.001]
  • [Cites] Cancer Biomark. 2010;9(1-6):177-92 [22112476.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1985-92 [10595928.001]
  • [Cites] J Immunol Methods. 2001 Jan 1;247(1-2):163-74 [11150547.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3230-9 [11309271.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1247-53 [11583952.001]
  • [Cites] Gut. 2002 Apr;50(4):520-4 [11889073.001]
  • [Cites] Nat Rev Immunol. 2002 Aug;2(8):569-79 [12154376.001]
  • [Cites] J Am Coll Surg. 2002 Aug;195(2):149-58 [12168960.001]
  • [Cites] Immunol Allergy Clin North Am. 2003 Feb;23(1):83-102, vi [12645880.001]
  • [Cites] Oncogene. 2003 Sep 25;22(41):6369-76 [14508517.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Am J Gastroenterol. 1995 Mar;90(3):353-65 [7872270.001]
  • (PMID = 22112468.001).
  • [ISSN] 1875-8592
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / P30 AR050948; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / P50 CA101955; United States / NCI NIH HHS / CA / U24 CA086359
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS402045; NLM/ PMC3430522
  •  go-up   go-down


3. Li ZX, Peng ZH, Ji FP, Yuan JY, Pan M, Liu Y, Wang Q: [Expression of E-cadherin and beta-catenin in Bowen's disease and squamous cell carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug;26(8):1245-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of E-cadherin and beta-catenin in Bowen's disease and squamous cell carcinoma].
  • OBJECTIVE: To investigate the involvement of E-cadherin-catenin adhesion system in Bowen's disease (BD) and cutaneous squamous cell carcinoma (SCC).
  • METHODS: Fifteen normal skin, 28 BD and 18 SCC specimens were stained with monoclonal antibodies against E-cadherin and beta-catenin.
  • RESULT: Normal skins strongly expressed membranous E-cadherin and beta-catenin, but their expression was remarkably reduced in BD and SCC.
  • Abnormal staining of beta-catenin was observed in the cytoplasm or cell nuclei of BD and SCC.
  • CONCLUSION: Abnormal expression of the E-cadherin/catenin complex is common in SCC and BD.
  • [MeSH-major] Bowen's Disease / metabolism. Cadherins / biosynthesis. Carcinoma, Squamous Cell / metabolism. Skin Neoplasms / metabolism. beta Catenin / biosynthesis


Advertisement
4. Inoue T, Kobayashi K, Sawada M, Ishizaki S, Ito H, Fujibayashi M, Tanaka M: Dermoscopic Features of Pigmented Bowen's Disease in a Japanese Female Mimicking Malignant Melanoma. Dermatol Res Pract; 2010;2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopic Features of Pigmented Bowen's Disease in a Japanese Female Mimicking Malignant Melanoma.
  • Various structures have been reported for dermoscopic features of pigmented Bowen's disease (BD), which could be a mimic of various pigmented skin lesions.
  • We suspected pigmented skin lesions including seborrheic keratosis, pigmented eccrine poroma, and malignant melanoma and excised completely with a 5 mm margin.
  • Histopathological features were consistent with a diagnosis of pigmented BD.
  • Although similar dermoscopic features might be revealed in pigmented skin lesions and it may occasionally be difficult to distinguish between pigmented BD and other pigmented skin lesions, dermoscopy would be useful in speculating pathologic features of pigmented BD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20811602.001).
  • [ISSN] 1687-6113
  • [Journal-full-title] Dermatology research and practice
  • [ISO-abbreviation] Dermatol Res Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2929512
  •  go-up   go-down


5. Matsumoto M, Ishiguro M, Ikeno F, Ikeda M, Kamijima R, Hirata Y, Saruta T, Kodama H: Combined Bowen disease and extramammary Paget disease. J Cutan Pathol; 2007 Dec;34 Suppl 1:47-51
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined Bowen disease and extramammary Paget disease.
  • BACKGROUND: The histological resemblance between extramammary Paget disease and Bowen disease has been described since Bowen's original article was published in 1912.
  • METHODS: We herein describe a case of vulval primary extramammary Paget disease in a 61-year-old women with the histological features of Bowen disease.
  • RESULTS: Histological examination of a biopsy specimen showed acanthosis with full-thickness cellular atypia, focal hyperkeratosis and parakeratosis in the epidermis, and no characteristic Paget cells were observed.
  • However, histological examination of an operative specimen revealed areas characteristic of Paget disease and Bowen disease.
  • Overall, the areas characteristic of Bowen disease and Paget disease occupied 6% and 32% of the total operative specimen, respectively.
  • Immunohistochemical findings showed carcinoembryonic antigen to be expressed in areas containing Paget cells, but not in the areas characteristic of Bowen disease.
  • CONCLUSIONS: Our findings indicated that primary extramammary Paget disease and squamous cell carcinoma in situ arose multifocally from a common cell in the epidermis.
  • [MeSH-major] Bowen's Disease / pathology. Carcinoma in Situ / pathology. Neoplasms, Multiple Primary / pathology. Paget Disease, Extramammary / pathology. Skin Neoplasms / pathology. Vulvar Neoplasms / pathology

  • Genetic Alliance. consumer health - Paget Disease.
  • Genetic Alliance. consumer health - Paget disease, extramammary.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17997739.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 68238-35-7 / Keratins
  •  go-up   go-down


6. Lukas VanderSpek LA, Pond GR, Wells W, Tsang RW: Radiation therapy for Bowen's disease of the skin. Int J Radiat Oncol Biol Phys; 2005 Oct 1;63(2):505-10
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy for Bowen's disease of the skin.
  • PURPOSE: To assess the clinical outcome in the radiation therapy (RT) of squamous carcinoma in situ of the skin (Bowen's disease).
  • METHODS AND MATERIALS: A retrospective review was performed on 44 patients with Bowen's disease treated at Princess Margaret Hospital from April 1985 to November 2000.
  • RT was the primary treatment for 32 patients, whereas 12 received RT for residual disease after local ablative therapy.
  • There was no standard fractionation regimen: some physicians prescribed high doses, as for invasive skin cancer, whereas others prescribed lower doses because of the noninvasive nature of the disease, a sensitive anatomic location (e.g., extremity), or large treatment area.
  • Local control was defined as the lack of persistent or recurrent disease at the treated site for the follow-up period.
  • One recurrence was Bowen's disease (local); the others were squamous cell carcinoma (one local, one marginal).
  • Four patients experienced a new squamous lesion at a distant cutaneous site.
  • All but 3 patients were disease-free at last follow-up, 1 of whom died with distant, but not local disease.
  • CONCLUSIONS: Radiation therapy is an effective treatment option for Bowen's disease of the skin.
  • [MeSH-major] Bowen's Disease / radiotherapy. Skin Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Bowen's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168842.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Kvlividze O, Gogiashvili L, Burkadze G: The characteristics of human papillomavirus expression and cell proliferation in actinic keratosis and Bowen's disease of the skin. Georgian Med News; 2006 Jul;(136):108-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The characteristics of human papillomavirus expression and cell proliferation in actinic keratosis and Bowen's disease of the skin.
  • The aim of our study was to elucidate the characteristics of HPV expression and cell proliferation in actinic keratosis and Bowen's disease of the skin.
  • We examined immunocompetent patients with premalignant lesions of the skin such as actinic keratosis and Bowen's disease.
  • Actinic keratosis and Bowen's disease failed to show the specific clinical features, therefore, they can not be diagnosed based on clinical signs only and morphological examination seems to be mandatory.
  • The immunohistochemical study has showed that in both actinic keratosis and Bowen's disease HPV was positive in 60%, and 40% were HPV-negative suggesting the similar incidence of HPV infection in these premalignant lesions.
  • Our results suggest that HPV(+)/p53(+) types of actinic keratosis and Bowen's disease are characterized by higher proliferation activity in comparison to HPV(-)/p53(+) types, and expression of Bcl-2 is associated with HPV-negativity, therefore, these premalignant lesions of the skin require immunohistochemical examination with evaluation of expressions of human papillomavirus, proliferation marker PCNA and anti-apoptotic protein Bcl-2.
  • The differential diagnosis of actinic keratosis and Bowen's disease should be based on the following immunohistochemical criteria: incidences of positivity for p53, Bcl-2 and PCNA are similar, but expression intensity and anatomical localization are different: their expressions are higher in Bowen's disease, positive cells are found primarily in upper epidermis in actinic keratosis, while whole epithelium is involved in Bowen's disease.
  • [MeSH-major] Antibodies, Viral / immunology. Bowen's Disease / virology. Human papillomavirus 6 / immunology. Photosensitivity Disorders / virology. Skin Neoplasms / virology
  • [MeSH-minor] Adult. Aged. Apoptosis. Cell Proliferation. Humans. Incidence. Middle Aged. Papillomavirus Infections / epidemiology. Papillomavirus Infections / pathology. Papillomavirus Infections / virology

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16905862.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 0 / Antibodies, Viral
  •  go-up   go-down


8. Venkatarajan S, LeLeux TM, Yang D, Rosen T, Orengo I: Porokeratosis of Mibelli: Successful treatment with 5 percent topical imiquimod and topical 5 percent 5-fluorouracil. Dermatol Online J; 2010;16(12):10
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Porokeratosis of Mibelli (PM) is a clonal disorder of keratinization.
  • With a 7.5 percent risk of malignancy, PM should be treated to prevent transformation into squamous cell carcinoma, Bowen disease, or basal cell carcinoma.
  • [MeSH-minor] Administration, Cutaneous. Aged, 80 and over. Carcinoma, Basal Cell / complications. Humans. Leg. Male. Remission Induction. Skin Neoplasms / complications. Skin Neoplasms / prevention & control

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21199636.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antimetabolites; 0 / Immunologic Factors; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Weisenseel P, Prinz J, Korting H: [Treatment of paraungual HPV73-positive Bowen disease with imiquimod cream]. Hautarzt; 2006 Apr;57(4):309-10, 312
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of paraungual HPV73-positive Bowen disease with imiquimod cream].
  • [Transliterated title] Therapie eines parungualen HPV-73-positiven Morbus Bowen mit Imiquimod-Creme.
  • Bowen disease - a squamous cell carcinoma in situ - is associated with oncogenic human papilloma viruses (HPV).
  • The association is best established for genital Bowen disease but also holds for extragenital lesions.
  • The immunomodulatory substance imiquimod is used for the treatment of HPV-induced skin disorders.
  • In the case of paraungual Bowen disease, established treatment options as excision, cryosurgery, radiotherapy or laser treatment might cause persistent nail damage.
  • We successfully treated HPV73-positive Bowen disease in this location with topical imiquimod.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Bowen's Disease / drug therapy. Nail Diseases / drug therapy. Papillomaviridae. Papillomavirus Infections / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Drug Administration Schedule. Follow-Up Studies. Humans. Male. Middle Aged. Occlusive Dressings. Polymerase Chain Reaction. Skin / pathology

  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1997 May 15;79(10):1911-7 [9149017.001]
  • [Cites] J Am Acad Dermatol. 2001 Mar;44(3):462-70 [11209116.001]
  • [Cites] Lancet Infect Dis. 2001 Oct;1(3):189-98 [11871495.001]
  • [Cites] Clin Exp Dermatol. 2002 Oct;27(7):571-7 [12464152.001]
  • [Cites] Clin Exp Dermatol. 2003 Nov;28 Suppl 1:13-5 [14616805.001]
  • [Cites] Acta Derm Venereol. 2004;84(2):168-9 [15206706.001]
  • [Cites] Int J STD AIDS. 2001 Nov;12 (11):722-9 [11589811.001]
  • [Cites] Vet J. 1997 Nov;154(3):175-88 [9414951.001]
  • (PMID = 15800757.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; P1QW714R7M / imiquimod
  •  go-up   go-down


10. Talghini S, Halimi M, Baybordi H: Expression of P27, Ki67 and P53 in squamous cell carcinoma, actinic keratosis and Bowen disease. Pak J Biol Sci; 2009 Jun 15;12(12):929-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of P27, Ki67 and P53 in squamous cell carcinoma, actinic keratosis and Bowen disease.
  • This study aims at evaluating the expression of P27, Ki67 and P53 in Squamous Cell Carcinoma (SCC), Actinic Keratosis (AK) and Bowen Disease (BD) specimens.
  • In an analytic-descriptive setting, skin biopsy specimens of 45 patients were evaluated in three 15-case groups including BD, AK and SCC specimens.
  • Fifteen normal skin biopsy specimens were obtained and used as the control group.
  • Ki67 was expressed in 0.8, 23.7, 12.3 and 19.3% of the cells in the normal skin, AK, BD and SCC groups, respectively.
  • P27 was positive in 23.4, 26.2, 25.9 and 4.5% of specimens in the normal skin, AK, BD and SCC groups, respectively.
  • This rate was significantly the lowest in the SCC group.
  • P53 expression was detected in 26.6, 41.8 and 54.6% of the assessed cells in the AK, BD and SCC groups, respectively.
  • There was no expression of P53 in the normal skin specimens.
  • This rate was significantly the highest again in the SCC group.
  • [MeSH-major] Bowen's Disease / metabolism. Carcinoma, Squamous Cell / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Keratosis, Actinic / metabolism. Ki-67 Antigen / metabolism. Skin Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Cyclin-Dependent Kinase Inhibitor p27. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Skin / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19777788.001).
  • [ISSN] 1028-8880
  • [Journal-full-title] Pakistan journal of biological sciences : PJBS
  • [ISO-abbreviation] Pak. J. Biol. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


11. Hu A, Moore C, Yu E, Mount G, Jordan K, Vujovic O, Gilchrist J, Doyle PC: Evaluation of patient-perceived satisfaction with photodynamic therapy for Bowen disease. J Otolaryngol Head Neck Surg; 2010 Dec;39(6):688-96

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of patient-perceived satisfaction with photodynamic therapy for Bowen disease.
  • OBJECTIVE: to formally evaluate patient concerns and patient-perceived satisfaction with photodynamic therapy (PDT) using topical application of 5-aminolevulinic acid for Bowen disease (BD).
  • METHODS: a novel 32-item self-reported patient satisfaction questionnaire was mailed out to all patients treated with PDT for BD from January 1, 2000, to March 31, 2008.
  • RESULTS: one hundred thirty-two adults were treated with PDT for BD over this time period.
  • A majority (> 90%) indicated a very favourable impression of the effectiveness of PDT for BD and that side effects were mild.
  • The most substantial limitations with PDT were social limitations secondary to treatment (26%), self-consciousness (28%), and skin appearance in the immediate posttreatment period (30%).
  • CONCLUSIONS: PDT is favourably received by those diagnosed with BD.
  • PDT resulted in a high degree of perceived satisfaction for those patients with BD.
  • Based on these data, PDT is supported as a viable method of treatment for BD.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Bowen's Disease / drug therapy. Photochemotherapy. Photosensitizing Agents / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21144365.001).
  • [ISSN] 1916-0216
  • [Journal-full-title] Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
  • [ISO-abbreviation] J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


12. Petrella LI, Pereira WC, Valle HA, Issa PR, Martins CJ, Machado JC: Study of superficial basal cell carcinomas and Bowen disease by qualitative and quantitative ultrasound biomicroscopy approach. Conf Proc IEEE Eng Med Biol Soc; 2010;2010:5999-6002
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of superficial basal cell carcinomas and Bowen disease by qualitative and quantitative ultrasound biomicroscopy approach.
  • In the present work the ultrasound biomicroscopy (UBM) technique is applied in the study of cutaneous cell carcinomas in vitro, including superficial basal cell carcinomas (BCC) and Bowen disease (BD) cases.
  • The characteristic histological structures for each studied tumor type were well identified in the images.
  • The IBC values observed in the two carcinoma types inside the affected region, were different between them, next to 10(-4) [Sr(-1).mm(-1)] for superficial BCC tissues, and to 10(-5) [Sr(-1).mm(-1)1] for BD tissues; moreover, in the deeper dermis (slight affected region) the backscatter was next to 10(-3) [Sr(-1).mm(-1)] for both tissue groups, and agrees with the values obtained for healthy skin both, in this study and in previous works.
  • [MeSH-major] Bowen's Disease / pathology. Bowen's Disease / ultrasonography. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / ultrasonography. Microscopy, Acoustic / methods. Skin Neoplasms / pathology. Skin Neoplasms / ultrasonography
  • [MeSH-minor] Biopsy. Humans. Imaging, Three-Dimensional. Skin / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21097109.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Guenova E, Hoetzenecker W, Metzler G, Röcken M, Schaller M: Multicentric Bowen disease in linear porokeratosis. Eur J Dermatol; 2007 Sep-Oct;17(5):439-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric Bowen disease in linear porokeratosis.
  • This type of porokeratosis is particularly susceptible to malignant degeneration e.g. to Bowen disease, a squamous cell carcinoma (SCC) in situ with the potential for significant lateral spread.
  • Here we report a case of linear porokeratosis on the left leg of a 56-year-old man, complicated with two lesions of multicentric Bowen disease.
  • [MeSH-major] Bowen's Disease / etiology. Porokeratosis / complications. Skin Neoplasms / etiology
  • [MeSH-minor] Humans. Male. Middle Aged. Skin / pathology

  • Genetic Alliance. consumer health - Linear porokeratosis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673390.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


14. Brannan PA, Anderson HK, Kersten RC, Kulwin DR: Bowen disease of the eyelid successfully treated with imiquimod. Ophthal Plast Reconstr Surg; 2005 Jul;21(4):321-2
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowen disease of the eyelid successfully treated with imiquimod.
  • We present a case of Bowen disease affecting the eyelid that was successfully treated with imiquimod.
  • The tumor was treated with imiquimod for 3 months, leading to complete resolution of the disease both clinically and histopathologically.
  • Imiquimod was safely used on the eyelid in this case and may avoid extensive periocular tumor excision and reconstruction in Bowen disease.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Bowen's Disease / drug therapy. Eyelid Neoplasms / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16052154.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


15. Terada T: Pigmented Bowen disease arising in pigmented reticulated seborrheic keratosis. Int J Clin Oncol; 2010 Dec;15(6):608-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pigmented Bowen disease arising in pigmented reticulated seborrheic keratosis.
  • A 76-year-old man consulted to our hospital complaining of a black tumor of the temporal head.
  • A clinical diagnosis of basal cell carcinoma was made, and an excision with wide margins was performed.
  • This case suggests that pigmented Bowen disease can arise in pigmented reticulated seborrheic keratosis.
  • [MeSH-major] Bowen's Disease / etiology. Carcinoma, Basal Cell / complications. Keratosis, Seborrheic / complications. Skin Neoplasms / etiology

  • Genetic Alliance. consumer health - Keratosis, seborrheic.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Dermatol Surg Oncol. 1988 Jul;14(7):765-9 [3292613.001]
  • [Cites] Pathol Int. 2002 Nov;52(11):740-6 [12685552.001]
  • [Cites] J Cutan Pathol. 1989 Dec;16(6):348-52 [2533222.001]
  • [Cites] Mt Sinai J Med. 1974 Nov-Dec;41(6):792-801 [4279330.001]
  • [Cites] J Cutan Pathol. 1978 Dec;5(6):361-7 [154527.001]
  • [Cites] J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):440-4 [2145328.001]
  • [Cites] Br J Dermatol. 1991 Mar;124(3):287-90 [1826848.001]
  • [Cites] Tohoku J Exp Med. 2005 Jul;206(3):271-5 [15942157.001]
  • [Cites] Australas J Dermatol. 2006 May;47(2):106-8 [16637805.001]
  • [Cites] Plast Reconstr Surg. 1998 Aug;102(2):453-5; discussion 456-8 [9703085.001]
  • (PMID = 20425131.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Sun JD, Barr RJ: Papillated Bowen disease, a distinct variant. Am J Dermatopathol; 2006 Oct;28(5):395-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillated Bowen disease, a distinct variant.
  • Bowen disease usually presents as an irregular, asymptomatic, scaly or crusted erythematous plaque that can occur anywhere on the skin.
  • This papillated variant of Bowen disease exhibits keratinocytes with prominent perinuclear halos suggestive of koilocytic change associated with human papillomavirus (HPV) infections.
  • Classic Bowen disease has been associated in previous studies with a variety of HPV types, especially types 16, 18, and 31.
  • Twenty-six patients with papillated Bowen disease were evaluated.
  • Papillated Bowen disease is distinct from other variants, including the verrucous-hyperkeratotic type.
  • [MeSH-major] Bowen's Disease / virology. Genetic Variation. Papillomaviridae / pathogenicity. Papillomavirus Infections / virology. Skin Neoplasms / virology. Tumor Virus Infections / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17012913.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes, HPV; 0 / DNA, Viral
  •  go-up   go-down


17. Gupta S, Nutan, Dogra S, Kanwar AJ: Bowen Disease over photoprotected site in an Indian male. Dermatol Online J; 2009;15(10):16
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowen Disease over photoprotected site in an Indian male.
  • Bowen Disease is squamous cell carcinoma in situ in which the basement membrane is intact on histopathology.
  • [MeSH-major] Bowen's Disease / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19951634.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Carroll KA, Pierce J, Kovarik CL: Perianal Bowen disease in a child with human immunodeficiency virus. Pediatr Dermatol; 2010 Mar-Apr;27(2):166-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perianal Bowen disease in a child with human immunodeficiency virus.
  • We report a case of perianal Bowen disease in an HIV-positive child.
  • Histologic sections revealed squamous cell carcinoma in situ.
  • [MeSH-major] Anus Neoplasms / virology. Bowen's Disease / virology. Carcinoma in Situ / virology. Carcinoma, Squamous Cell / virology. HIV Infections / complications. Papillomavirus Infections / etiology. Skin Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20537068.001).
  • [ISSN] 1525-1470
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Hara H, Honda A, Suzuki H, Matsukura T: Detection of human papillomavirus type 34 in Bowen's disease on the pubic area. J Eur Acad Dermatol Venereol; 2006 Feb;20(2):206-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of human papillomavirus type 34 in Bowen's disease on the pubic area.
  • We describe an 86-year-old man with Bowen's disease on the pubic area.
  • Histopathological findings showed those of Bowen's disease and harboured human papillomavirus type 34 DNA.
  • Genital, but not skin, human papillomaviruses are responsible for Bowen's disease on the skin.
  • [MeSH-major] Bowen's Disease / diagnosis. Papillomaviridae / isolation & purification. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. DNA, Viral / analysis. Diagnosis, Differential. Groin. Humans. Male

  • Genetic Alliance. consumer health - Bowen's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16441634.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


20. Motolese I, Mazzera L, Frezzotti P, Motolese PA, Motolese E: Use of amniotic membrane transplantation in isolated conjunctival Bowen disease: a case report. Eur J Ophthalmol; 2010 May-Jun;20(3):604-7
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of amniotic membrane transplantation in isolated conjunctival Bowen disease: a case report.
  • PURPOSE: To report a case of isolated conjunctival Bowen disease treated with surgical resection and amniotic membrane transplantation.
  • CONCLUSIONS: Treatment options and treatment studies of Bowen disease are difficult because there are a variety of different protocols and the success of the management depends on several factors (body site, lesion size, number of lesions, and thickness).
  • [MeSH-major] Amnion / transplantation. Bowen's Disease / surgery. Conjunctival Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037899.001).
  • [ISSN] 1120-6721
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


21. Kaminaka C, Yamamoto Y, Yonei N, Kishioka A, Kondo T, Furukawa F: Phenol peels as a novel therapeutic approach for actinic keratosis and Bowen disease: prospective pilot trial with assessment of clinical, histologic, and immunohistochemical correlations. J Am Acad Dermatol; 2009 Apr;60(4):615-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenol peels as a novel therapeutic approach for actinic keratosis and Bowen disease: prospective pilot trial with assessment of clinical, histologic, and immunohistochemical correlations.
  • OBJECTIVE: Our purpose was to investigate the efficacy and prognostic relevance of phenol peels in Japanese patients with actinic keratosis and Bowen disease using clinical and histologic criteria.
  • We evaluated parameters for epidermal thickness, proliferation, dysplasia, and apoptosis, and clinical characteristics to correlate phenol peels with assessments of efficacy, patient-selection criteria, and risk for transformation to cutaneous squamous cell carcinoma.
  • Statistically, differences in clinical improvement with peels and the number of treatment sessions correlated with histology, personal history of skin cancer, tumor thickness, and cyclin A expression.
  • CONCLUSION: We conclude that phenol peels are very effective for treating precancerous lesions of actinic keratosis and Bowen disease.
  • [MeSH-major] Bowen's Disease / drug therapy. Keratolytic Agents / therapeutic use. Keratosis, Actinic / drug therapy. Phenols / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19293009.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratolytic Agents; 0 / Phenols
  •  go-up   go-down


22. Micali G, Nasca MR, De Pasquale R: Erythroplasia of Queyrat treated with imiquimod 5% cream. J Am Acad Dermatol; 2006 Nov;55(5):901-3
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imiquimod is an immune response-modifying agent with potent antiviral and antitumor activity effective in the treatment of various skin disorders, including in situ carcinoma of the skin (Bowen's disease).
  • The case of a 64-year-old man affected by an in situ carcinoma of the glans mucosa, namely erythroplasia of Queyrat, successfully treated with imiquimod 5% cream is described.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Carcinoma in Situ / drug therapy. Erythroplasia / drug therapy. Penile Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17052503.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


23. Fantini F, Greco A, Cesinaro AM, Surrenti T, Peris K, Vaschieri C, Marconi A, Giannetti A, Pincelli C: Pathologic changes after photodynamic therapy for Basal cell carcinoma and Bowen disease: a histologic and immunohistochemical investigation. Arch Dermatol; 2008 Feb;144(2):186-94
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic changes after photodynamic therapy for Basal cell carcinoma and Bowen disease: a histologic and immunohistochemical investigation.
  • OBJECTIVE: To investigate the in vivo reactions and the mechanisms of cell death after photodynamic therapy (PDT) for cutaneous carcinomas.
  • Photodynamic therapy is a new treatment modality for nonmelanoma skin cancers.
  • DESIGN: Skin biopsy specimens were obtained sequentially after PDT for basal cell carcinoma and in situ squamous cell carcinoma (Bowen disease).
  • We used electron microscopy to evaluate cell damage at the ultrastructural level.
  • MAIN OUTCOME MEASURES: Evidence of the mechanisms of tumor cell damage after PDT, detection of histologic and/or immunohistochemical signs of apoptosis, and time course of the tumor destruction and inflammatory reaction.
  • In basal cell carcinoma, nodule damage progressed from scant apoptotic cells seen at the dermal-epithelial junction to massive destruction seen after 1 and 2 days.
  • CONCLUSIONS: This study defines the time course and characteristics of the skin tumor response to PDT.
  • [MeSH-major] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18283175.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


24. Szeimies RM, Karrer S, Bäcker H: [Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma]. Hautarzt; 2005 May;56(5):430-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma].
  • [Transliterated title] Therapieoptionen bei epithelialen Hauttumoren Aktinische Keratosen, Morbus Bowen, spinozelluläres Karzinom und Basalzellkarzinom.
  • There has been worldwide a significant rise in the incidence of epithelial skin tumors and their precursors in the past years with an increased number of younger patients affected.
  • In the following article different therapeutic approaches for actinic keratoses, Bowen's disease, basal cell carcinoma and squamous cell carcinoma are presented and analysed.
  • [MeSH-major] Risk Assessment / methods. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Bowen's Disease / diagnosis. Bowen's Disease / therapy. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Cryotherapy / methods. Curettage / methods. Humans. Keratosis / diagnosis. Keratosis / therapy. Practice Guidelines as Topic. Practice Patterns, Physicians'. Risk Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2001 May;177(5):240-6 [11398609.001]
  • [Cites] Br J Dermatol. 2001 Mar;144(3):567-74 [11260016.001]
  • [Cites] Int J Dermatol. 2001 Nov;40(11):709-13 [11737438.001]
  • [Cites] J Am Acad Dermatol. 2001 Mar;44(3):462-70 [11209116.001]
  • [Cites] J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):414-8 [10459115.001]
  • [Cites] Dermatologica. 1979;158(5):368-72 [437226.001]
  • [Cites] Int J Dermatol. 2004 Sep;43(9):687-92 [15357755.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]
  • [Cites] Clin Exp Dermatol. 1999 Jul;24(4):338-9 [10457144.001]
  • [Cites] J Dermatol Surg Oncol. 1989 Apr;15(4):424-31 [2925988.001]
  • [Cites] J Am Acad Dermatol. 2002 Aug;47(2):258-62 [12140473.001]
  • [Cites] J Am Acad Dermatol. 1982 Nov;7(5):631-2 [7142470.001]
  • [Cites] J Drugs Dermatol. 2004 Jul-Aug;3(4):401-7 [15303784.001]
  • [Cites] Dermatol Surg. 2004 Sep;30(9):1214-8 [15355363.001]
  • [Cites] Br J Dermatol. 1999 Oct;141(4):633-41 [10583109.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2003 Mar;17(2):167-70 [12705745.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):759-64 [10940063.001]
  • [Cites] Br J Dermatol. 2000 Apr;142(4):752-7 [10792227.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:43-9 [14616349.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):148-56 [15270884.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] Arch Dermatol. 2002 Nov;138(11):1498-502 [12437457.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 1):517-20 [15056141.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12(6):558-61 [12459527.001]
  • [Cites] J Am Acad Dermatol. 1998 Mar;38(3):438-42 [9520026.001]
  • [Cites] Australas J Dermatol. 2000 Feb;41(1):19-30 [10715896.001]
  • [Cites] J Am Acad Dermatol. 2004 Oct;51(4):547-55 [15389189.001]
  • [Cites] Clin Dermatol. 2001 May-Jun;19(3):328-38 [11479045.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1284-5 [15492200.001]
  • [Cites] J Dermatolog Treat. 2003 Jun;14(2):99-106 [12775317.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):141-7 [15270883.001]
  • [Cites] Br J Cancer. 1997;76(1):100-6 [9218740.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):832-40 [11298545.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1286-7 [15492202.001]
  • [Cites] Br J Dermatol. 2003 Mar;148(3):539-43 [12653747.001]
  • [Cites] J Am Acad Dermatol. 1997 Jan;36(1):72-7 [8996264.001]
  • [Cites] Dermatol Surg. 2003 Nov;29(11):1150-3; discussion 1153 [14641346.001]
  • [Cites] Dermatol Surg. 2001 Feb;27(2):143-6 [11207687.001]
  • [Cites] J Am Acad Dermatol. 2003 Sep;49(3):483-6 [12963913.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1766-72 [15541449.001]
  • [Cites] Br J Dermatol. 1996 Nov;135(5):766-71 [8977678.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Sep;17(9):720-6 [1820764.001]
  • [Cites] Clin Radiol. 1986 Jan;37(1):33-4 [3514075.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):714-21 [15097955.001]
  • [Cites] Clin Ther. 2002 Jun;24(6):990-1000 [12117087.001]
  • [Cites] Lasers Surg Med. 2004;34(2):114-9 [15004822.001]
  • (PMID = 15815888.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 48
  •  go-up   go-down


25. Maury G, Girard C, Michot C, Guillot B, Dereure O: [Multiple Bowen disease of the lower limbs in elderly women: a rare clinical subset involving therapeutic difficulties]. Ann Dermatol Venereol; 2009 Jun-Jul;136(6-7):508-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple Bowen disease of the lower limbs in elderly women: a rare clinical subset involving therapeutic difficulties].
  • [Transliterated title] Maladies de Bowen multiples des membres inférieurs chez les femmes âgées : une forme clinique particulière et de traitement difficile.
  • BACKGROUND: Cutaneous Bowen's disease (CBD) is a form of intraepithelial squamous cell carcinoma that usually presents as a solitary lesion.
  • We report four similar cases of a peculiar and well-delimited clinical subset of multiple Bowen's disease seen in the lower limbs in elderly women and associated with specific therapeutic problems.
  • OBSERVATIONS: Four women aged over 70 years presented with multiple CBD limited to the lower limbs associated with squamous cell and superficial basal cell carcinomas along with actinic keratosis.
  • [MeSH-major] Bowen's Disease / complications. Lower Extremity. Skin Neoplasms / complications
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / complications. Female. Humans. Keratosis, Actinic / complications. Photochemotherapy. Sunlight / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19560611.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


26. Stetsenko GY, McFarlane RJ, Chien AJ, Fleckman P, Swanson P, George E, Argenyi ZB: Subungual Bowen disease in a patient with epidermodysplasia verruciformis presenting clinically as longitudinal melanonychia. Am J Dermatopathol; 2008 Dec;30(6):582-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subungual Bowen disease in a patient with epidermodysplasia verruciformis presenting clinically as longitudinal melanonychia.
  • Lesions usually develop in early childhood, persist, and may eventuate in cutaneous squamous cell carcinoma, usually in sun-exposed areas.
  • We present a case of a 34-year-old African American woman with EV with a 9-month history of a right index finger ungual longitudinal pigmented band and nail splitting.
  • The findings are of a squamous cell carcinoma in situ arising in association with EV with incidental melanocytic hyperplasia.
  • To the best of our knowledge, this is first report of a subungual presentation of this condition with associated melanonychia.
  • [MeSH-major] Bowen's Disease / diagnosis. Carcinoma, Squamous Cell / diagnosis. Epidermodysplasia Verruciformis / diagnosis. Hyperpigmentation / diagnosis. Nail Diseases / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Incidental Findings. Nails / pathology


27. Yoon TY, Kim HJ, Kim JW, Kim MK, Lee JY: Bowen's disease concealed by purpura. J Dermatol; 2007 Jan;34(1):65-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowen's disease concealed by purpura.
  • Bowen's disease (BD) is a squamous cell carcinoma in situ characterized by a well-demarcated scaly erythematous thin plaque with an irregular outline.
  • Clinically, BD is frequently misdiagnosed as superficial basal cell carcinoma, patches of dermatitis, psoriasis, lichen planus, actinic keratosis, benign lichenoid keratosis, irritated seborrheic keratosis, viral warts, amelanotic melanoma or melanoma.
  • However, angiosarcoma has not usually been mentioned in the differential diagnosis of BD before.
  • Herein, we describe two cases of BD presenting as purpura on the scalp of the elderly with an initial clinical suspicion of angiosarcoma.
  • [MeSH-major] Bowen's Disease / complications. Purpura / complications. Scalp. Skin Neoplasms / complications
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Bowen's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204105.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


28. Mun JH, Kim SH, Jung DS, Ko HC, Kwon KS, Kim MB: Dermoscopic features of Bowen's disease in Asians. J Eur Acad Dermatol Venereol; 2010 Jul;24(7):805-10
Genetic Alliance. consumer health - Bowen's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopic features of Bowen's disease in Asians.
  • BACKGROUND: Previously, dermoscopic features of Bowen's disease (BD) were extensively investigated in two studies, but there were some discrepancies.
  • The dispute necessitated a further study concerning the dermoscopic features of BD.
  • OBJECTIVE: To describe the dermoscopic features of BD in Asians and to assess dermoscopy as a post-treatment monitoring tool of BD.
  • MATERIALS AND METHODS: Dermoscopic examinations of histopathologically diagnosed 26 BD lesions were performed to evaluate for the presence of various dermoscopic features.
  • In addition, the correlating changes of dermoscopic features and histopathological results before and after treatments were assessed in five patients with BD.
  • The most frequent dermoscopic findings of BD were vascular structures (96%) and a scaly surface (96%).
  • Skin biopsy from treated lesions disclosed clearance of BD in four patients who had no vascular structures but remaining BD in the patient whose dermoscopic finding displayed no disappearance of vascular structures.
  • CONCLUSIONS: Vascular structures, especially glomerular vessels plus a scaly surface, were common dermoscopic findings of BD in Asians.
  • In addition, existence of dermoscopic vascular structures after treatment appears to be associated with residual disease.
  • [MeSH-major] Bowen's Disease / pathology. Dermoscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20015173.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


29. Leibovitch I, Selva D, Huilgol S, Davis G, Dodd T, James CL: Intraepithelial sebaceous carcinoma of the eyelid misdiagnosed as Bowen's disease. J Cutan Pathol; 2006 Apr;33(4):303-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraepithelial sebaceous carcinoma of the eyelid misdiagnosed as Bowen's disease.
  • BACKGROUND: Sebaceous carcinoma (SC) is well known for its ability to masquerade clinically and histologically as a variety of periocular conditions resulting in a delayed diagnosis.
  • We present a series of periocular SC cases and discuss the difficulties in histopathological diagnosis when this tumor presents with a Bowenoid pattern of intraepithelial spread.
  • Histopathologically, 87.5% of cases were misdiagnosed as Bowen's disease (BD) on the initial biopsy.
  • Six of these cases showed no invasive disease on the initial biopsy and were eventually found to be invasive SC on subsequent excisions.
  • Delay in diagnosis ranged from 0 to 56 months.
  • CONCLUSIONS: SC should always be considered in the histological differential diagnosis of any eyelid lesion which resembles BD, particularly if the upper eyelid is involved or if multivacuolated cytoplasmic clear cell changes are seen.
  • [MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Bowen's Disease / diagnosis. Eyelid Neoplasms / diagnosis. Mohs Surgery. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Bowen's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630181.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


30. Gu Y, Zhu L, Feng RE, Lang JH: [Clinicopathologic analysis of 19 cases of usual type vulvar intraepithelial neoplasia]. Zhonghua Fu Chan Ke Za Zhi; 2009 Mar;44(3):167-70
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic analysis of 19 cases of usual type vulvar intraepithelial neoplasia].
  • OBJECTIVE: To reclassify the patients with former diagnosis of vulvar intraepithelial neoplasia (VIN)II, VINII-III, VINIII, Bowen disease and Bowenoid papulosis according to the 2004 modified terminology of International Society for the Study of Vulvar Disease (ISSVD) and evaluate the effects of surgical treatment.
  • METHODS: According to the 2004 modified terminology of ISSVD, a retrospective review of the histological slides of 19 cases, who diagnosed as VINII, VINII-III, VINIII, Bowen disease and Bowenoid papulosis treated in Peking Union Medical College Hospital from 1999 to 2006, were performed to reclassify by pathologist and the clinicopathologic data were also analyzed.
  • RESULTS: According to the 2004 modified terminology of ISSVD, all 19 cases were reclassified as usual type VIN and were belonged to the subtype of warty type except one, the only Bowen disease patient whose one of focuses belonged to the subtype of basaloid type and the other focus belonged to the subtype of warty type.
  • There were two cases recurred during follow-up period, and were cured by second surgical treatment and the focuses of recurrence site were still diagnosed as warty type VIN.
  • CONCLUSIONS: The patients with former diagnosis of VINII, VINII-III, VINIII, Bowen disease and Bowenoid papulosis are basically reclassified as usual type VIN (warty type) according to the 2004 modified terminology of ISSVD.
  • The results showed that the diagnosis of VIN could be simplified by new terminology.
  • [MeSH-major] Bowen's Disease / pathology. Carcinoma in Situ / pathology. Neoplasm Staging / standards. Vulvar Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19570438.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


31. Doffoel-Hantz V, Sparsa A, Marin B, Durox H, Bonnetblanc JM, Bédane C: [The value of photodynamic therapy in the treatment of Bowen's disease]. Ann Dermatol Venereol; 2008 Dec;135(12):822-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The value of photodynamic therapy in the treatment of Bowen's disease].
  • [Transliterated title] Intérêt de la photothérapie dynamique topique dans la prise en charge de la maladie de Bowen.
  • BACKGROUND: While the standard treatments for Bowen's disease (BD) (surgery, cryotherapy and antimitotic agents) are efficient, they are associated with extensive scarring.
  • In this paper we confirm that photodynamic therapy using topical aminolevulinic acid provides effective treatment for this disease.
  • PATIENTS AND METHODS: Twenty-two patients with a total of 38 cases of BD were included in this retrospective single-centre study between 2001 and 2006.
  • The study criteria consisted of patient age and gender, site and area of lesions, number of patients with multiple patches of BD and/or large lesions, tolerance of the treatment, clinical response and quality of wound healing at 3, 6 and 12 months.
  • RESULTS: Seven men and 15 women of median age: 76 years (interquartile range: [69-82]) with 38 cases of Bowen's diseases were treated with photodynamic therapy.
  • Eight patients were presenting multiple patches of BD (> or = three lesions), and large lesions were noted in 11 cases.
  • DISCUSSION: This open retrospective study confirmed the good efficacy of photodynamic therapy in the treatment of BD in terms of both clinical remission and cosmetic results.
  • [MeSH-major] Bowen's Disease / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Bowen's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19084691.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


32. Auepemkiate S, Thongsuksai P, Boonyaphiphat P: P16(INK4A) expression in Bowen's disease and Bowenoid papulosis. J Med Assoc Thai; 2006 Sep;89(9):1460-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P16(INK4A) expression in Bowen's disease and Bowenoid papulosis.
  • BACKGROUND: Bowen's disease (BD) is a skin carcinoma in situ occurring over the entire body surface.
  • Increased p16(INK4A) (p16) tumor suppressor protein expression has been demonstrated in relation to the progression of cutaneous squamous neoplasms.
  • OBJECTIVE: To evaluate the difference in p16 expression between Bowen's disease and Bowenoid papulosis.
  • MATERIAL AND METHOD: Biopsies of 46 cases of BD in the period 1994 - 2003 and 14 cases of BP during 1987 - 2003 in the Anatomical Pathology Unit, Department of Pathology, Faculty of Medicine, Prince of Songkla University, Thailand were studied by immunohistochemical methods using the P16 kit (CINTec Histology Kit, clone E6H4, Code-Nr.
  • RESULTS: P16 expression was positive in 37 of 46 BD cases (80.4%) which was higher than that of BP (6 of 14 cases or 42.9%) (p value < 0.05, Chi-square test).
  • The expression among the three groups of BD: extragenital (28 of 35), chronic arsenical-related (7 of 8) and genital lesions (2 of 3) was not significantly different (p value = 0.734, Chi-square test).
  • CONCLUSION: P16 expression was more frequent in BD than BP.
  • [MeSH-major] Bowen's Disease / metabolism. Carcinoma, Squamous Cell / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Precancerous Conditions / metabolism. Skin Neoplasms / metabolism

  • Genetic Alliance. consumer health - Bowen's Disease.
  • Genetic Alliance. consumer health - Bowenoid Papulosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17100385.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


33. Mitsuishi T, Nakatake M, Kaneko T, Ohara K, Kato T, Iida K, Iwabu Y, Tokunaga K, Sata T, Kawana S, Yamada O: Evaluation of telomerase activity in non-genital Bowen's disease. J Eur Acad Dermatol Venereol; 2009 Jun;23(6):668-72
Genetic Alliance. consumer health - Bowen's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of telomerase activity in non-genital Bowen's disease.
  • We investigated the level of telomerase activity (TA) in 17 specimens of non-genital Bowen's disease (BD) and in 14 specimens of skin without sun exposure (non-exposed skin) using a non-isotopic PCR-based telomeric repeat amplification protocol (TRAP) assay.
  • Expression of human telomerase reverse transcriptase (hTERT; the catalytic subunit of telomerase) was also evaluated by immunochemistry in the non-genital BD tissues.
  • Moderate to high levels of TA were detected in 41.2% of 17 non-genital BD specimens (P = 0.001).
  • In contrast, TA was not evident in non-exposed skin.
  • Immunohistochemistry showed that nucleolin expression was associated with high TA levels in non-genital BD.
  • Our results also revealed differences of TA levels among non-genital BD specimens.
  • These results suggested that cellular DNA damage caused by ultraviolet irradiation might be associated with an increase of TA in non-genital BD.
  • Among non-genital BD specimens, 4 out of 17 (23.5%) showed high levels of TA (median relative TA value: 79.8%; P = 0.003), which might be associated with immortalization or transformation to invasive squamous cell carcinoma.
  • [MeSH-major] Bowen's Disease / enzymology. Telomerase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19250332.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


34. Sezer E, Yuksek J: Warty and clear-cell Bowen's disease successfully treated with photodynamic treatment. Photodermatol Photoimmunol Photomed; 2010 Feb;26(1):48-50
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Warty and clear-cell Bowen's disease successfully treated with photodynamic treatment.
  • Clear cell Bowen's disease (BD) is a rare histopathological subtype of BD, characterized by epidermal atypical keratinocytes with clear-cell changes exceeding 80% of the tumor population.
  • Warty and clear cell Bowen's disease (WCCBD) is a recently described variant of clear cell BD, with verrucous and hyperkeratotic surface changes in addition to pathological features consisting of an extremely acanthotic epidermis, hyperkeratosis and clear-cell changes.
  • Herein we present a 72-year-old man with a 1-year history of tumoral lesion located on the left cheek with a diagnosis of WCCBD, in whom we achieved excellent result with photodynamic treatment.
  • [MeSH-major] Aminolevulinic Acid / pharmacology. Bowen's Disease / drug therapy. Head and Neck Neoplasms / drug therapy. Photochemotherapy. Photosensitizing Agents / pharmacology. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20070841.001).
  • [ISSN] 1600-0781
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


35. Bagazgoitia L, Cuevas J, Juarranz A: Expression of p53 and p16 in actinic keratosis, bowenoid actinic keratosis and Bowen's disease. J Eur Acad Dermatol Venereol; 2010 Feb;24(2):228-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53 and p16 in actinic keratosis, bowenoid actinic keratosis and Bowen's disease.
  • INTRODUCTION: Bowen's disease (BD) and bowenoid actinic keratosis (bAK) have traditionally been differentiated according to the presence or absence of dysplasia in the follicular epithelium. p16 has been suggested to be a useful tool to make the differential diagnosis between BD and AK and as a marker of bad prognosis.
  • MATERIALS: Five biopsies of BD, five of AK and five of bAK where stained for p53 and p16.
  • RESULTS: All lesions showed positive immunostaining of p53, affecting to the lower two thirds of the epidermis in BD and bAK, and only the basal layer in non-bAK.
  • All the BD and bAK cases were positive for p16, showing a similar immunostaining pattern, whereas no staining was observed in non-bAK.
  • DISCUSSION AND CONCLUSION: These findings suggest a common pathogenic mechanism for BD and bAK. bAK might have worse prognosis than AK. p16 might not be useful as a tool for differential diagnosis between AK and BD because bAK and BD show an extremely similar immunohistochemical pattern.
  • [MeSH-major] Bowen's Disease / metabolism. Genes, p16. Keratosis, Actinic / metabolism. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Bowen's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19515076.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


36. Sakakibara A, Kamijima M, Shibata S, Yasue S, Kono M, Tomita Y: Dermoscopic evaluation of vascular structures of various skin tumors in Japanese patients. J Dermatol; 2010 Apr;37(4):316-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopic evaluation of vascular structures of various skin tumors in Japanese patients.
  • Dermoscopic analysis of skin tumor has been mainly focused on pigmented structures.
  • Recently, several different morphological types of vessels were found to be well associated with pigmented or non-pigmented skin tumors in white subjects.
  • As little statistical information on the various pigmented skin tumor vessels of Japanese patients has been reported, we therefore tried to evaluate the association between various vascular structures and 741 tumor lesions of Japanese patients.
  • Vascular structures were dermoscopically recognized in 41 of 102 cases of melanoma, 104 of 119 basal cell carcinoma (BCC), 86 of 257 seborrheic keratosis (SK), 35 of 210 dermal and compound nevus (DN/CN), six of 12 squamous cell carcinoma (SCC) and 16 of 41 Bowen disease (BD).
  • The structures of arborizing and glomerular vessels statistically revealed diagnostic specificity for BCC and BD, respectively, and hairpin vessels were helpful for differentiating SK from other pigmented tumors, as already reported in white patients.
  • The most common vascular pattern observed in melanoma was the linear-irregular structure, but this pattern in Japanese patients had less diagnostic value than in white patients, because its sensitivity was not significantly higher than in SCC.
  • [MeSH-major] Dermoscopy. Neovascularization, Pathologic / pathology. Skin Neoplasms / blood supply
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Asian Continental Ancestry Group. Blood Vessels / pathology. Bowen's Disease / blood supply. Bowen's Disease / diagnosis. Carcinoma, Basal Cell / blood supply. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / diagnosis. Female. Humans. Japan. Keratosis, Seborrheic / blood. Keratosis, Seborrheic / diagnosis. Male. Melanoma / blood supply. Melanoma / diagnosis. Middle Aged. Nevus / blood supply. Nevus / diagnosis. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20507400.001).
  • [ISSN] 1346-8138
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R: Cutaneous squamous carcinoma in situ (Bowen's disease): treatment with Mohs micrographic surgery. J Am Acad Dermatol; 2005 Jun;52(6):997-1002
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous squamous carcinoma in situ (Bowen's disease): treatment with Mohs micrographic surgery.
  • BACKGROUND: Bowen's disease (BD), also known as squamous intraepidermal carcinoma, is a malignant skin tumor with a potential to progress to invasive carcinoma.
  • OBJECTIVE: We sought to report a large series of patients with BD treated with Mohs micrographic surgery (MMS).
  • METHODS: This prospective, multicenter, case series included all patients in Australia treated with MMS for BD, who were monitored by the Skin and Cancer Foundation between 1993 and 2002.
  • In 20% the tumor was initially misdiagnosed as basal cell carcinoma or squamous cell carcinoma.
  • CONCLUSION: The low 5-year recurrence rate of BD with MMS emphasizes the importance of margin-controlled excision, especially in the head and neck area where tissue preservation is essential.
  • [MeSH-major] Bowen's Disease / surgery. Mohs Surgery. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Bowen's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15928618.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


38. Calzavara-Pinton PG, Venturini M, Sala R, Capezzera R, Parrinello G, Specchia C, Zane C: Methylaminolaevulinate-based photodynamic therapy of Bowen's disease and squamous cell carcinoma. Br J Dermatol; 2008 Jul;159(1):137-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylaminolaevulinate-based photodynamic therapy of Bowen's disease and squamous cell carcinoma.
  • BACKGROUND: Photodynamic therapy (PDT) with methylaminolaevulinate (MAL) is an approved noninvasive treatment option for actinic keratosis and Bowen's disease (BD), two precursors of invasive squamous cell carcinoma (SCC).
  • OBJECTIVES: To assess efficacy, prognostic features, tolerability and cosmetic outcome of MAL-PDT for the treatment of BD and SCC.
  • METHODS: In total, 112 biopsy-proven lesions of BD and SCC in 55 subjects were treated in an outpatient setting.
  • A multivariate logistic regression model, with robust variance estimation, showed that cell atypia was the only statistically significant independent predictor of the treatment outcome at 3 months.
  • CONCLUSIONS: MAL-PDT may represent a valuable, effective and well tolerated treatment option with good cosmetic outcome for superficial, well-differentiated (Broders' scores I and II) BD and microinvasive SCC.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Bowen's Disease / drug therapy. Carcinoma, Squamous Cell / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489606.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


39. van Egmond S, Hoedemaker C, Sinclair R: Successful treatment of perianal Bowen's disease with imiquimod. Int J Dermatol; 2007 Mar;46(3):318-9
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of perianal Bowen's disease with imiquimod.
  • Although perianal Bowen's disease (BD) is a relatively uncommon malignancy, it is being detected with increasing frequency.
  • The effectiveness of different treatment modalities, ranging from aggressive wide local excision with skin grafting to the application of a topical immune response modifier, remains uncertain.
  • To our knowledge only two cases of perianal BD, successfully treated with imiquimod, have been reported.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Bowen's Disease / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343595.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  • [Number-of-references] 7
  •  go-up   go-down


40. Corbalán-Vélez R, Ruiz-Macia JA, Brufau C, López-Lozano JM, Martínez-Barba E, Carapeto FJ: [Clear cells in cutaneous squamous cell carcinoma]. Actas Dermosifiliogr; 2009 May;100(4):307-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clear cells in cutaneous squamous cell carcinoma].
  • [Transliterated title] Las células claras en el carcinoma espinocelular cutáneo.
  • INTRODUCTION: Although few cases of squamous cell carcinoma (SCC) with clear cells have been published, we believe that these cells are often present in SCC.
  • Advanced or established SCCs and SCCs associated with Bowen disease contained a larger proportion of clear cells.
  • We defined 2 histological patterns: a) clear cells around the keratin pearls of SCCs arising from pre-existing actinic keratosis and with indirect signs of human papilloma virus infection in hair follicles; and b) clear cells that simulate adnexal differentiation in lesions arising on pre-existing Bowen disease lesions.
  • DISCUSSION: Clear cells are frequently observed in SCC, though large numbers of clear cells are present only in certain SCCs.
  • The appearance of clear cells in SCCs is progressive and they are only present in more advanced SCC.
  • The presence of clear cells is suggestive of adnexal differentiation; however, in the majority of cases, their presence is due to infiltration of normal adnexal structures by the cells of pagetoid Bowen disease.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19463234.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


41. Nakanishi G, Fujii K, Asagoe K, Tanaka T, Iwatsuki K: Human papillomavirus genome integration in multifocal vulvar Bowen's disease and squamous cell carcinoma. Clin Exp Dermatol; 2009 Dec;34(8):e965-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus genome integration in multifocal vulvar Bowen's disease and squamous cell carcinoma.
  • Human papillomavirus (HPV) is an important aetiological agent in cervical carcinomas and in malignant skin tumours.
  • On histological examination, multifocal vulvar Bowen's disease (BD) and invasive squamous cell carcinoma (SCC) were found.
  • An amplification of papillomavirus oncogene transcripts (APOT) assay showed that two locations of BD had only episome-derived HPV16 transcripts, but the other two sites of BD and the nodule of invasive SCC had HPV16 transcripts derived from integration.
  • Sequencing analysis revealed that the invasive SCC had its integration site at 8q24, the Myc locus.
  • Our results suggest that the APOT assay in multiple sites of the same patient may be a valuable tool for evaluation of the clinical degree of malignancy for vulvar BD.
  • [MeSH-major] Bowen's Disease / pathology. Carcinoma, Squamous Cell / pathology. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Aged. Cell Transformation, Viral / genetics. Female. Humans. Virus Integration


42. Hoshina D, Akiyama M, Hata H, Aoyagi S, Sato-Matsumura KC, Shimizu H: Eccrine porocarcinoma and Bowen's disease arising in a seborrhoeic keratosis. Clin Exp Dermatol; 2007 Jan;32(1):54-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eccrine porocarcinoma and Bowen's disease arising in a seborrhoeic keratosis.
  • We observed a case of eccrine porocarcinoma and Bowen's disease (BD) occurring synchronously, forming one lesion in a SK on the abdomen.
  • This case suggests an implication of pre-existing SK in the subsequent development of both BD and eccrine porocarcinoma.
  • [MeSH-major] Bowen's Disease / pathology. Carcinoma / pathology. Eccrine Glands. Keratosis, Seborrheic / pathology. Skin Neoplasms / pathology. Sweat Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Bowen's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Exp Dermatol. 2008 May;33(3):350-1 [18261140.001]
  • (PMID = 17004985.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


43. Saglam O, Salama M, Meier F, Chaffins M, Ma C, Ormsby A, Lee M: Immunohistochemical staining of palisading basal cells in Bowen's disease and basal involvement in actinic keratosis: contrasting staining patterns suggest different cells of origin. Am J Dermatopathol; 2008 Apr;30(2):123-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining of palisading basal cells in Bowen's disease and basal involvement in actinic keratosis: contrasting staining patterns suggest different cells of origin.
  • Actinic keratosis (AK) and Bowen's disease (BD) are common patterns of in situ squamous cell carcinoma of the epidermis.
  • In contrast, BD features atypical squamous cells in all portions of the epidermis but initially leaves basal cells in palisades along the basement membrane.
  • To characterize immunohistochemically keratocyte proliferation in AK and Palisading Basal Cells (PBC) in BD, we stained microarray samples of 45 AK and 25 BD with Molecular Immunology Borstel (MIB-1).
  • Subsequent immunostaining of full mounted sections examined 11 BD, 7 AK, and 4 examples of psoriasis for MIB-1 (as a proliferative marker) and p53 (as a cell cycle regulatory marker).
  • BD with typical PBCs stained positive for both markers throughout the epidermis, except for the basal layer.
  • Normal epidermis adjacent to the lesions in AK and BD biopsies stained sparsely in the basal layers.
  • The correlation of different histologic patterns of epidermal involvement with different immunohistochemical patterns of stains argues for different cells of origin for BD versus AK.
  • Lack of expression of proliferative antigens in palisading basal cells in BD provides evidence that PBCs are not the cell of origin for BD.
  • [MeSH-major] Bowen's Disease / pathology. Carcinoma, Basal Cell / pathology. Keratosis / pathology. Ki-67 Antigen / metabolism. Skin Neoplasms / pathology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biopsy, Needle. Cohort Studies. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Immunohistochemistry. Male. Middle Aged. Sensitivity and Specificity. Staining and Labeling / methods

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360114.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


44. Mandekou-Lefaki I, Delli F, Koussidou-Eremondi T, Mourellou-Tsatsou O, Dionyssopoulos A: Imiquimod 5% cream: a new treatment for Bowen's disease. Int J Tissue React; 2005;27(1):31-8
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod 5% cream: a new treatment for Bowen's disease.
  • Bowen's disease (BD) is a squamous cell carcinoma in situ.
  • Recent studies suggest that human papilloma virus plays an important role in the development of BD.
  • We investigated whether imiquimod 5%, a topical immune response modifier, is an effective treatment for BD in five immunocompetent patients.
  • Our results suggest that topical imiquimod 5% is an effective treatment for BD through its viral and antitumor effects.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Antiviral Agents / therapeutic use. Bowen's Disease / drug therapy. Carcinoma, Squamous Cell / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15847103.001).
  • [ISSN] 0250-0868
  • [Journal-full-title] International journal of tissue reactions
  • [ISO-abbreviation] Int J Tissue React
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Antiviral Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


45. Bordbar A, Dias D, Cabral A, Beck S, Boon ME: Assessment of cell proliferation in benign, premalignant and malignant skin lesions. Appl Immunohistochem Mol Morphol; 2007 Jun;15(2):229-35
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of cell proliferation in benign, premalignant and malignant skin lesions.
  • A deeper understanding of the variance of epidermal cell proliferation may eventually increase the reproducibility of diagnostic classification.
  • A prospective study of 46 consecutive, unselected biopsies from benign (keratoacanthoma n=14), premalignant (actinic keratosis n=15 and Bowen disease n=10) and malignant (squamous cell carcinoma n=7) skin lesions was studied to assess the presence and extent of differences in expression of the proliferation marker Ki-67 using a monoclonal antibody directed against a c-DNA defined subsegment (MIB-1) and a noncross-linking, proprietary fixative BoonFix.
  • MIB-1 was expressed in the adjacent, non-affected skin in a scattered to confluent linear pattern in the basal/suprabasal cell layer.
  • An interesting feature in actinic keratosis as well as in Bowen disease was the expression of MIB-1 in the epithelium lining the hair follicles.
  • In Bowen disease, MIB-1 was observed throughout the full thickness of the epidermis, unequivocally separating this entity from others under study.
  • In invasive squamous cell carcinoma, MIB-1 expression was not consistent between and within cases.
  • These results warrant further study of modulation of cell proliferation in actinic keratosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525640.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / MIB-1 antibody
  •  go-up   go-down


46. Lipoff JB, Scope A, Busam KJ, Nehal KS: Melanonychia following mohs surgery for recurrent squamous cell carcinoma in situ of the nail bed. J Cutan Med Surg; 2008 Jul-Aug;12(4):194-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanonychia following mohs surgery for recurrent squamous cell carcinoma in situ of the nail bed.
  • BACKGROUND: Longitudinal melanonychia (LM) is characterized by the appearance of a longitudinal pigmented band in the nail plate.
  • Melanonychia can occur from many causes, including racial predisposition, trauma, drugs, pregnancy, Addison disease, Peutz-Jeghers syndrome, Laugier-Hunziker syndrome, Bowen disease, onychomycosis, benign nail matrix nevi, and melanoma.
  • OBJECTIVE: We present a case of diffuse melanonychia developing several months following Mohs surgery for a human papillomavirus-induced recurrent squamous cell carcinoma in situ of the nail bed.
  • CONCLUSIONS: This case illustrates the diagnostic dilemma in determining the etiology of the melanonychia and considers the differential diagnosis.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Melanosis / pathology. Melanosis / surgery. Mohs Surgery. Nail Diseases / surgery

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18627701.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Hama N, Ohtsuka T, Yamazaki S: Detection of mucosal human papilloma virus DNA in bowenoid papulosis, Bowen's disease and squamous cell carcinoma of the skin. J Dermatol; 2006 May;33(5):331-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of mucosal human papilloma virus DNA in bowenoid papulosis, Bowen's disease and squamous cell carcinoma of the skin.
  • Human papilloma virus (HPV) is known to be an etiologic agent for benign warts of the skin.
  • Recently, HPV have been detected in malignant skin and mucosal diseases suggesting that HPV infection can induce malignant skin tumors.
  • In the present study, we examined the presence of mucosal HPV DNA in normal tissue, Bowen's disease (BD), Bowenoid papulosis (BP) and squamous cell carcinoma (SCC) of the skin.
  • We detected the HPV DNA with polymerase chain reactions, and identified the type by DNA sequencing.
  • In the results, we detected HPV DNA in none of the 17 normal controls, two of the three BP (66.7%), one of the 21 BD (4.8%), and six of the 26 SCC of the skin samples (23.0%).
  • The occurrence rates of HPV in BP and SCC were significantly elevated compared to that of normal controls (P < 0.01 and P < 0.01, respectively).
  • In addition, the occurrence rate of HPV in BP was significantly elevated compared to that of BD (P < 0.05).
  • The case of BD with positive HPV DNA showed HPV 31.
  • Of the six cases of SCC with positive HPV DNA, one case showed HPV 16, another case HPV 34, and the other four cases HPV 31.
  • These results showed that mucosal HPV, including HPV 31 and 16, could be detected in SSC of the skin.
  • Mucosal HPV, not only the epidermodysplasia verruciformis type, appear to induce malignant skin tumors.
  • [MeSH-major] Bowen's Disease / virology. Carcinoma, Squamous Cell / virology. Papillomaviridae / isolation & purification. Skin Neoplasms / virology


48. Liao WT, Yu CL, Lan CC, Lee CH, Chang CH, Chang LW, You HL, Yu HS: Differential effects of arsenic on cutaneous and systemic immunity: focusing on CD4+ cell apoptosis in patients with arsenic-induced Bowen's disease. Carcinogenesis; 2009 Jun;30(6):1064-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential effects of arsenic on cutaneous and systemic immunity: focusing on CD4+ cell apoptosis in patients with arsenic-induced Bowen's disease.
  • Bowen's disease (BD), a carcinoma in situ of the skin, has been identified as an early lesion in arsenic carcinogenesis.
  • Patients with arsenic-induced Bowen's disease (As-BD) showed both cutaneous and systemic immune dysfunctions.
  • We set out to evaluate the interactions between keratinocytes and lymphocytes in the context of As-BD carcinogenesis.
  • Our results showed that As-BD lesions demonstrated a significant dermal CD4+ cell, an essential regulator of proper tumor immunity, undergoing apoptosis.
  • In addition, it was found that the As-BD patients have lower percentage of peripheral CD4+ cells as compared with control subjects.
  • However, the CD4+ cells from As-BD patients were less susceptible to arsenic-induced apoptosis, due to reduced tumor necrosis factor receptor 1 expression.
  • This sFasL-containing keratinocyte supernatant was able to induce comparable CD4+ cell apoptosis for both patients and controls.
  • Using immunofluorescent staining, increased FasL was observed in keratinocytes of As-BD lesions and Fas was expressed among infiltrating CD4+ cells.
  • Our findings suggested that systemically, the percentage of CD4+ cells was decreased in the peripheral blood of As-BD patients.
  • However, once infiltrated into the As-BD lesions, the selective CD4+ cell apoptosis might be mediated by FasL from keratinocytes.
  • This additional tumor-anti-immune phenomenon present in the cutaneous environment provides a reasonable explanation for frequent occurrence of arsenic cancers in the skin.
  • [MeSH-major] Apoptosis / drug effects. Arsenic / toxicity. Bowen's Disease / immunology. CD4-Positive T-Lymphocytes / drug effects. Skin Neoplasms / immunology
  • [MeSH-minor] Aged. Cell Transformation, Neoplastic / drug effects. Cells, Cultured. Fas Ligand Protein / metabolism. Female. Humans. Immunity, Active / drug effects. Keratinocytes / drug effects. Keratinocytes / immunology. Keratinocytes / metabolism. Male. Middle Aged

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19376847.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fas Ligand Protein; N712M78A8G / Arsenic
  •  go-up   go-down


49. Hida Y, Kubo Y, Murao K, Arase S: Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res; 2007 May;299(2):103-6
Saccharomyces Genome Database. Saccharomyces Genome Database .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strong expression of a longevity-related protein, SIRT1, in Bowen's disease.
  • SIRT1 regulates cell survival via deacetylation of p53 and forkhead transcription factors, and overexpression of SIRT1 is reported to be essential for cell growth and survival in some kinds of cancer.
  • To elucidate the role of SIRT1 in human skin carcinogenesis, we have examined SIRT1 protein expression in 20 cases each of squamous cell carcinoma (SCC), basal cell carcinoma (BCC), Bowen's disease (BD), and actinic keratosis (AK) by immunohistochemical analysis.
  • Overexpression of SIRT1 is frequently observed in all kinds of non-melanoma skin cancers included in this study.
  • In particular, strong expression was observed in all cases of BD.
  • In addition, no obvious difference between AK and SCC was observed in the expression of SIRT1, suggesting that overexpression of SIRT1 may have some relevance to the early stage of skin carcinogenesis.
  • We suppose that SIRT1 could be one of the critical targets for future therapy with the aim of inhibiting cell proliferation and promoting apoptosis in non-melanoma skin cancers.
  • [MeSH-major] Bowen's Disease / metabolism. Sirtuins / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Apoptosis / physiology. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Proliferation. Gene Expression Regulation, Neoplastic. Humans. Keratosis / metabolism. Keratosis / pathology. Sirtuin 1

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17180656.001).
  • [ISSN] 0340-3696
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins
  •  go-up   go-down


50. Ghosh P, Banerjee M, De Chaudhuri S, Das JK, Sarma N, Basu A, Giri AK: Increased chromosome aberration frequencies in the Bowen's patients compared to non-cancerous skin lesions individuals exposed to arsenic. Mutat Res; 2007 Aug 15;632(1-2):104-10
Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased chromosome aberration frequencies in the Bowen's patients compared to non-cancerous skin lesions individuals exposed to arsenic.
  • Despite of exposure at similar extent, only 15-20% of individuals show arsenic induced skin lesions including Bowen's disease (BD).
  • Previously we have reported the significant increase in CA in the individuals with arsenic induced skin lesions when compared to individuals without any skin lesions, drinking arsenic contaminated water at similar extent.
  • Presently, a matched case-control study was performed to examine whether biomarkers such as chromosomal aberrations can predict the development of arsenic induced Bowen's (in situ carcinoma) diseases.
  • Chromosomal aberrations (both chromosome and chromatid types) and mitotic index were analyzed from the lymphocytes of 25 cases of Bowen's patient which was compared to matched control from the individuals with arsenic induced non-cancerous skin lesions such as raindrop pigmentation, keratosis of palm and sole, hypo and hyper pigmentation.
  • Chromosomal aberrations/cell, chromosome type aberrations and total percentage of aberrant cells were significantly higher in cases compared to control (p<0.01).
  • [MeSH-major] Arsenic Poisoning / complications. Bowen's Disease / genetics. Chromosome Aberrations. Skin Diseases / chemically induced. Skin Diseases / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17600756.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Water Pollutants, Chemical; N712M78A8G / Arsenic
  •  go-up   go-down


51. Corbalán-Vélez R, Ruiz-Maciá JA, Brufau C, Carapeto FJ: [Cutaneous squamous cell carcinoma and human papillomavirus]. Actas Dermosifiliogr; 2007 Nov;98(9):583-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous squamous cell carcinoma and human papillomavirus].
  • [Transliterated title] Carcinoma espinocelular cutáneo y papilomavirus (VPH).
  • The relationship between mucosal human papillomavirus (HPV) and cervical carcinoma or anogenital squamous cell carcinoma (SCC) is becoming increasingly evident, whereas a link between HPV and other cutaneous SCCs is less clear.
  • Recent studies have reported links between epidermodysplasia-verruciformis-associated HPV and extragenital cutaneous SCC, particularly in immunosuppressed patients, although immunocompetent patients have also been affected.
  • Mucosal HPV could also be linked to some types of Bowen disease and certain SCCs of the fingers, oropharyngeal mucosa, etc.
  • HPV might be associated with worse prognosis of SCC, with implications for clinical practice including greater risk of metastasis.
  • [MeSH-major] Carcinoma, Squamous Cell / virology. Papillomavirus Infections / complications. Skin Neoplasms / virology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961447.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 134
  •  go-up   go-down


52. Patel MJ, Stockfleth E: Does progression from actinic keratosis and Bowen's disease end with treatment: diclofenac 3% gel, an old drug in a new environment? Br J Dermatol; 2007 May;156 Suppl 3:53-6
Hazardous Substances Data Bank. DICLOFENAC .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does progression from actinic keratosis and Bowen's disease end with treatment: diclofenac 3% gel, an old drug in a new environment?
  • Progression from actinic keratosis (AK) and Bowen's disease (BD) to invasive disease involves a complex cascade of events.
  • Given its mechanism of action, we hypothosize that diclofenac 3% gel may have potential to halt the progression of actinic keratoses (AKs) in the setting of field cancerisation and BD.
  • We report a series of five patients with BD, all treated with diclofenac 3% gel with clinical and histological clearance.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Bowen's Disease / drug therapy. Diclofenac / administration & dosage. Keratosis / drug therapy
  • [MeSH-minor] Administration, Topical. Disease Progression. Gels. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Bowen's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488408.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Gels; 144O8QL0L1 / Diclofenac
  •  go-up   go-down


53. Kivisaari AK, Kallajoki M, Ala-aho R, McGrath JA, Bauer JW, Königová R, Medvecz M, Beckert W, Grénman R, Kähäri VM: Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma. Br J Dermatol; 2010 Oct;163(4):726-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma.
  • BACKGROUND: Tumour-specific expression of matrix metalloproteinase (MMP)-7 has been noted in cutaneous squamous cell carcinomas (SCCs) in patients with recessive dystrophic epidermolysis bullosa (RDEB).
  • METHODS: Tissue microarrays of RDEB-associated SCC (n = 20), non-EB SCC (n = 60) and Bowen disease (n = 28) were immunostained for MMP-7, CD44 variant 3 (CD44v3) and HB-EGF.
  • Shedding of HB-EGF was studied in vitro using two cutaneous SCC cell lines.
  • The loss of HB-EGF in MMP-7-CD44v3 double-positive areas was interpreted to indicate shedding and activation of HB-EGF; this was also detected in Bowen disease indicating its importance in the early phase of SCC development.
  • Specific knockdown of MMP-7 expression in human cutaneous SCC cells by small interfering RNA inhibited shedding of HB-EGF and resulted in diminished activation of the EGF receptor (EGFR) and ERK1/2, and in reduced proliferation of SCC cells.
  • CONCLUSIONS: These findings provide evidence for the role of MMP-7 in promoting the growth of cutaneous SCCs by shedding HB-EGF, and identify EGFR signalling as a potential therapeutic target in RDEB-associated SCC and unresectable sporadic cutaneous SCC.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Intercellular Signaling Peptides and Proteins / metabolism. Matrix Metalloproteinase 7 / physiology. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Antigens, CD44 / metabolism. Cell Proliferation / drug effects. Dipeptides / pharmacology. Enzyme Activation. Female. Gene Knockdown Techniques. Heparin-binding EGF-like Growth Factor. Humans. Male. Matrix Metalloproteinase Inhibitors. Middle Aged. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Neoplasm Proteins / metabolism. Protease Inhibitors / pharmacology. RNA, Small Interfering / genetics. Receptor, Epidermal Growth Factor / physiology. Signal Transduction / physiology. Tumor Cells, Cultured. Young Adult

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. BJD © 2010 British Association of Dermatologists.
  • (PMID = 20586780.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / CD44V3,8-10; 0 / Dipeptides; 0 / HBEGF protein, human; 0 / Heparin-binding EGF-like Growth Factor; 0 / Intercellular Signaling Peptides and Proteins; 0 / Matrix Metalloproteinase Inhibitors; 0 / N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide; 0 / Neoplasm Proteins; 0 / Protease Inhibitors; 0 / RNA, Small Interfering; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.24 / MAPK1 protein, human; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


54. Hasegawa T, Suga Y, Mizuno Y, Haruna K, Ogawa H, Ikeda S: Efficacy of photodynamic therapy with topical 5-aminolevulinic acid using intense pulsed light for Bowen's disease. J Dermatol; 2010 Jul;37(7):623-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of photodynamic therapy with topical 5-aminolevulinic acid using intense pulsed light for Bowen's disease.
  • Photodynamic therapy (PDT) with topical 5-aminolevulinic acid (ALA) is reported to be an effective and safe treatment for superficial non-melanoma skin cancers.
  • We have developed an photodynamic therapy with topical delta-aminolevulinic acid (ALA-PDT) protocol using intense pulsed light (IPL) for treating Bowen's disease (BD).
  • Three patients diagnosed with BD by skin biopsy were recruited in this study.
  • The treated areas did not show any signs of BD for more than 1 year; therefore, it appeared that the affected areas showed improvement in all the patients.
  • ALA-PDT with IPL as a light source is well tolerated by patients and is beneficial for treating BD.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Bowen's Disease / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Bowen's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629828.001).
  • [ISSN] 1346-8138
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


55. Herman JM, Pierce LJ, Sandler HM, Griffith KA, Jabbari S, Hiniker SM, Johnson TM: Radiotherapy using a water bath in the treatment of Bowen's disease of the digit. Radiother Oncol; 2008 Sep;88(3):398-402
Hazardous Substances Data Bank. Water .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy using a water bath in the treatment of Bowen's disease of the digit.
  • PURPOSE: Bowen's disease (BD), a form of squamous cell carcinoma in situ, can transform into invasive squamous cell carcinoma and should be treated aggressively.
  • Although standard treatment for BD is electrodessication and curettage, radiotherapy (RT) can be used for those patients who are poor surgical candidates or when surgery could result in a poor cosmetic and functional outcome.
  • Surgical treatment of BD of the digit can result in poor function and sometimes amputation.
  • Here, we report our experience using a unique water bath technique to treat BD of the digit.
  • MATERIALS AND METHODS: This retrospective review evaluates the outcomes and toxicity of nine consecutive patients with BD of the digit treated with RT between 1999 and 2004.
  • CONCLUSIONS: These preliminary results demonstrate high rates of tumor control with minimal morbidity following definitive RT in the treatment of BD of the digit, and suggest that RT may be a viable treatment alternative to surgery for selected lesions.
  • Through a multidisciplinary assessment, treatment of BD of the digit can be individualized to optimize patient care.
  • [MeSH-major] Bowen's Disease / radiotherapy. Fingers. Skin Neoplasms / radiotherapy. Water

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18571754.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 059QF0KO0R / Water
  •  go-up   go-down


56. Zalaudek I, Kreusch J, Giacomel J, Ferrara G, Catricalà C, Argenziano G: How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part II. Nonmelanocytic skin tumors. J Am Acad Dermatol; 2010 Sep;63(3):377-86; quiz 387-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part II. Nonmelanocytic skin tumors.
  • Nonmelanoma skin cancer refers to a broad class of tumors, including actinic keratosis, basal cell carcinoma, and squamous cell carcinoma, and as a group these are the most frequent cancers occurring in light skinned humans.
  • In contrast to the rarity of amelanotic melanoma, nonmelanoma skin cancer commonly lacks pigmentation.
  • Dermoscopy improves the clinical diagnosis of nonpigmented skin tumors by allowing the visualization of specific vascular structures that are usually not visible to the naked eye.
  • Dermoscopic vascular patterns of several nonmelanocytic nonpigmented skin tumors, such as sebaceous hyperplasia, seborrheic keratosis, clear cell acanthoma, Bowen disease, or nodular cystic basal cell carcinoma are highly specific, allowing a ready diagnosis in most cases.
  • In the second part of this review of dermoscopic vascular structures of nonpigmented skin tumors, the dermoscopic patterns associated with benign and malignant nonmelanocytic skin tumors and recommendations for the management of these tumors will be discussed.
  • [MeSH-major] Dermoscopy / methods. Skin / blood supply. Skin Neoplasms / blood supply. Skin Neoplasms / diagnosis
  • [MeSH-minor] Blood Vessels / pathology. Bowen's Disease / blood supply. Bowen's Disease / diagnosis. Bowen's Disease / pathology. Carcinoma, Basal Cell / blood supply. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Education, Medical, Continuing. Female. Humans. Keratosis, Seborrheic / diagnosis. Keratosis, Seborrheic / pathology. Male. Melanoma, Amelanotic / blood supply. Melanoma, Amelanotic / diagnosis. Melanoma, Amelanotic / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20708470.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


57. Sidoroff A: [Photodynamic therapy of cutaneous epithelial malignancies. An evidence-based review]. Hautarzt; 2007 Jul;58(7):577-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During the last years photodynamic therapy (PDT) has progressively established itself as a standard treatment for non-melanoma skin cancer.
  • For Bowen disease and superficial basal cell carcinoma, PDT can be regarded as the first-line non-invasive treatment.
  • In nodular basal cell carcinoma, effectiveness for lesions up to a thickness of 2 mm is well documented.
  • [MeSH-major] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Keratosis / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy. Sunlight / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cosmet Laser Ther. 2003 Jun;5(2):107-10 [12850802.001]
  • [Cites] J Photochem Photobiol B. 1995 Jul;29(1):53-7 [7472803.001]
  • [Cites] Br J Dermatol. 2001 Sep;145(3):467-71 [11531838.001]
  • [Cites] J Dermatolog Treat. 2002;13 Suppl 1:S19-23 [12060513.001]
  • [Cites] J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):414-8 [10459115.001]
  • [Cites] Acta Derm Venereol. 1999 May;79(3):204-6 [10384917.001]
  • [Cites] Arch Dermatol. 2006 Jun;142(6):729-35 [16785375.001]
  • [Cites] Br J Dermatol. 2002 Apr;146(4):552-67 [11966684.001]
  • [Cites] J Am Acad Dermatol. 2002 Aug;47(2):258-62 [12140473.001]
  • [Cites] Arch Dermatol. 1998 Jul;134(7):821-6 [9681345.001]
  • [Cites] Acta Derm Venereol. 2005;85(6):483-90 [16396794.001]
  • [Cites] J Am Acad Dermatol. 2003 Feb;48(2):227-32 [12582393.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):33-40 [14732657.001]
  • [Cites] Br J Dermatol. 1995 Aug;133(2):282-8 [7547399.001]
  • [Cites] Arch Dermatol Res. 1996 Sep;288(10):561-4 [8919036.001]
  • [Cites] Br J Dermatol. 1994 Jun;130(6):743-51 [8011500.001]
  • [Cites] Br J Dermatol. 2000 Feb;142(2):338-9 [10730770.001]
  • [Cites] Br J Dermatol. 2007 May;156(5):793-801 [17419691.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):17-23 [14732655.001]
  • [Cites] J Dermatolog Treat. 2003 Jun;14(2):99-106 [12775317.001]
  • [Cites] Br J Dermatol. 2000 Oct;143(4):767-72 [11069454.001]
  • [Cites] Br J Dermatol. 2005 Apr;152(4):765-72 [15840111.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1029-36 [17034536.001]
  • [Cites] Br J Dermatol. 2001 Apr;144(4):832-40 [11298545.001]
  • [Cites] J Photochem Photobiol B. 1990 Jun;6(1-2):143-8 [2121931.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):41-6 [14732659.001]
  • [Cites] J Drugs Dermatol. 2003 Dec;2(6):629-35 [14711141.001]
  • [Cites] Br J Dermatol. 2000 Dec;143(6):1270-5 [11122032.001]
  • [Cites] Br J Dermatol. 2003 Mar;148(3):539-43 [12653747.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] Br J Dermatol. 1996 Nov;135(5):766-71 [8977678.001]
  • [Cites] J Drugs Dermatol. 2006 Feb;5(2 Suppl):17-25 [16485877.001]
  • [Cites] Arch Dermatol. 2003 Oct;139(10):1313-20 [14568836.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1242-9 [14674903.001]
  • [Cites] Acta Derm Venereol. 2005;85(5):424-8 [16159735.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):196-200 [15270891.001]
  • (PMID = 17522831.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 41
  •  go-up   go-down


58. Aguilar M, de Troya M, Martin L, Benítez N, González M: A cost analysis of photodynamic therapy with methyl aminolevulinate and imiquimod compared with conventional surgery for the treatment of superficial basal cell carcinoma and Bowen's disease of the lower extremities. J Eur Acad Dermatol Venereol; 2010 Dec;24(12):1431-6
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A cost analysis of photodynamic therapy with methyl aminolevulinate and imiquimod compared with conventional surgery for the treatment of superficial basal cell carcinoma and Bowen's disease of the lower extremities.
  • BACKGROUND: Superficial basal cell carcinoma (sBCC) and Bowen's disease (BD) are usually slow-growing, low-grade malignancies that mainly affect older persons.
  • SETTING: We collected data on 67 patients with 86 tumours (32 sBCC, 54 BD).
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Aminoquinolines / therapeutic use. Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Photochemotherapy / economics. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal compilation © 2010 European Academy of Dermatology and Venereology.
  • (PMID = 20456549.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid; 99011-02-6 / imiquimod
  •  go-up   go-down


59. Iosep I, Ivan L, Cozma L, Petrescu Z: [Cutaneous squamocellular carcinoma--immunohistochemical aspects]. Rev Med Chir Soc Med Nat Iasi; 2009 Apr-Jun;113(2):509-15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous squamocellular carcinoma--immunohistochemical aspects].
  • p53 gene is frequently founded mutated in nonmelanoma skin cancer like basocellular carcinoma, squamocellular carcinoma and equally in actinic keratosis and Bowen disease.
  • Our objective was to evaluate the role of p53 protein and proliferative factor Ki-67 on skin squamocellular carcinoma.
  • MATERIAL AND METHODS: We investigated a number of 21 cases of cutaneous squamocellular carcinoma using immunohistochemical research for p53, proliferative factor Ki-67 (avidine-biotine-peroxidase method).
  • CONCLUSION: p53 immunoreactivity was high in the majority of skin squamous cell carcinoma examined, probable related to an inactivated protein resulting from mutations of the p53 gene or other unclear molecular mechanisms.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / pathology. Immunohistochemistry. Ki-67 Antigen / analysis. Skin Neoplasms / chemistry. Skin Neoplasms / pathology. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21495358.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


60. Choudhary S, Nouri K, Elsaie ML: Photodynamic therapy in dermatology: a review. Lasers Med Sci; 2009 Nov;24(6):971-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Photodynamic therapy (PDT) is used for the prevention and treatment of non-melanoma skin cancer.
  • Until recently, clinically approved indications have been restricted to actinic keratoses, nodular and superficial basal cell carcinoma, and, since 2006, Bowen disease.
  • PDT is also used for the treatment of non-malignant conditions such as acne vulgaris and leishmaniasis, as well as for treating premature skin aging due to sun exposure.
  • Either cytotoxic effects resulting in tumor destruction or immunomodulatory effects improving inflammatory skin conditions are induced.
  • Treating superficial non-melanoma skin cancer, PDT has been shown to be highly efficient, despite the low level of invasiveness.
  • [MeSH-major] Photochemotherapy / methods. Skin Diseases / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Humans. Laser Therapy / methods. Lasers, Dye / therapeutic use. Lasers, Semiconductor / therapeutic use. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2001 Mar;144(3):567-74 [11260016.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2006 Oct;22(5):254-8 [16948827.001]
  • [Cites] J Drugs Dermatol. 2009 Jun;8(6):562-8 [19537381.001]
  • [Cites] J Am Acad Dermatol. 2003 Jun;48(6):893-6 [12789181.001]
  • [Cites] Clin Exp Dermatol. 2006 Sep;31(5):634-7 [16780497.001]
  • [Cites] Photodiagnosis Photodyn Ther. 2004 Dec;1(4):263-77 [25048431.001]
  • [Cites] Dermatol Surg. 2006 Jun;32(6):795-801; discussion 801-3 [16792644.001]
  • [Cites] Sci Am. 1988 Aug;259(2):68-75 [3064295.001]
  • [Cites] J Drugs Dermatol. 2004 Sep-Oct;3(5):548-51 [15552607.001]
  • [Cites] Cancer. 1997 Jun 15;79(12 ):2282-308 [9191516.001]
  • [Cites] Lasers Surg Med. 1995;17(1):2-31 [7564853.001]
  • [Cites] Actas Dermosifiliogr. 2008 Dec;99(10 ):779-87 [19091216.001]
  • [Cites] Arch Dermatol. 2006 Jun;142(6):729-35 [16785375.001]
  • [Cites] Arch Dermatol. 1998 Feb;134(2):207-14 [9487213.001]
  • [Cites] Acta Derm Venereol. 1994 Mar;74(2):117-9 [7911616.001]
  • [Cites] J Drugs Dermatol. 2008 Jul;7(7):627-32 [18664153.001]
  • [Cites] Dermatol Surg. 2002 Aug;28(8):742-4; discussion 744 [12174070.001]
  • [Cites] Photochem Photobiol. 2001 Aug;74(2):339-45 [11547574.001]
  • [Cites] J Dermatolog Treat. 2005;16(4):219-23 [16249142.001]
  • [Cites] Br J Dermatol. 2009 Jun;160(6):1308-14 [19416257.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2008 Nov;22(11):1302-11 [18624836.001]
  • [Cites] Acta Derm Venereol. 2008;88(3):288-90 [18480938.001]
  • [Cites] Dermatol Ther. 2005 May-Jun;18(3):242-52 [16229725.001]
  • [Cites] Br J Dermatol. 2009 May;160(5):1066-74 [19222455.001]
  • [Cites] Br J Cancer. 1998 May;77(9):1386-94 [9652753.001]
  • [Cites] Photochem Photobiol. 2008 Mar-Apr;84(2):407-14 [18221452.001]
  • [Cites] Lasers Surg Med. 2006 Jan;38(1):22-5 [16392149.001]
  • [Cites] Dermatol Surg. 2007 Jul;33(7):825-30 [17598848.001]
  • [Cites] J Photochem Photobiol B. 1999 Nov-Dec;53(1-3):53-9 [10672529.001]
  • [Cites] Arch Dermatol. 2007 Sep;143(9):1131-6 [17875873.001]
  • [Cites] Lasers Surg Med. 2007 Mar;39(3):203-9 [17311325.001]
  • [Cites] J Biomed Opt. 2008 May-Jun;13(3):030507 [18601524.001]
  • [Cites] Lasers Med Sci. 2002;17(3):173-86 [12181632.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] Clin Dermatol. 2001 May-Jun;19(3):328-38 [11479045.001]
  • [Cites] J Photochem Photobiol B. 2002 Nov;68(2-3):147-55 [12468210.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2009 May;23 (5):550-5 [19415804.001]
  • [Cites] Br J Dermatol. 2006 Dec;155(6):1262-9 [17107399.001]
  • [Cites] Lasers Med Sci. 2004;18(4):179-83 [15042420.001]
  • [Cites] Br J Dermatol. 2007 Feb;156(2):320-8 [17223873.001]
  • [Cites] Lasers Surg Med. 1999;25(1):51-9 [10421886.001]
  • [Cites] Ann Plast Surg. 2007 Nov;59(5):484-8 [17992139.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2007 Feb;23 (1):35-6 [17254035.001]
  • [Cites] Acta Derm Venereol. 1999 Nov;79(6):451-5 [10598759.001]
  • [Cites] J Invest Dermatol. 2006 Dec;126(12):2679-86 [16841035.001]
  • [Cites] J Am Acad Dermatol. 2006 Mar;54(3):524-6 [16488310.001]
  • [Cites] Lasers Med Sci. 2004;19(3):139-49 [15503248.001]
  • [Cites] J Am Acad Dermatol. 2006 Apr;54(4):647-51 [16546587.001]
  • [Cites] J Photochem Photobiol B. 2000 Nov;58(2-3):149-55 [11233643.001]
  • [Cites] Br J Dermatol. 2007 Mar;156(3):516-20 [17300242.001]
  • [Cites] Photomed Laser Surg. 2005 Apr;23(2):202-5 [15910187.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):41-6 [14732659.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Aug;20(7):823-8 [16898905.001]
  • [Cites] Int J Dermatol. 2007 Nov;46(11):1180-4 [17988339.001]
  • [Cites] Acta Derm Venereol. 2008;88(5):480-3 [18779886.001]
  • [Cites] Aust N Z J Surg. 1991 May;61(5):340-8 [2025186.001]
  • [Cites] J Drugs Dermatol. 2007 Oct;6(10):1010-6 [17966178.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] Dermatol Surg. 2009 Apr;35(4):586-92 [19309347.001]
  • [Cites] J Am Acad Dermatol. 2008 Mar;58(3):387-94 [18280335.001]
  • [Cites] Eur J Dermatol. 2008 Sep-Oct;18(5):547-53 [18693158.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2009 Feb;25(1):57-8 [19152520.001]
  • [Cites] Lasers Surg Med. 2007 Apr;39(4):302-10 [17457834.001]
  • [Cites] Acta Derm Venereol. 2005;85(5):424-8 [16159735.001]
  • [Cites] G Ital Dermatol Venereol. 2009 Feb;144(1):79-83 [19218913.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 1997 Oct-Dec;13(5-6):181-5 [9542754.001]
  • (PMID = 19653060.001).
  • [ISSN] 1435-604X
  • [Journal-full-title] Lasers in medical science
  • [ISO-abbreviation] Lasers Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  • [Number-of-references] 68
  •  go-up   go-down


61. Ortiz-Mendoza CM, Acosta-Sánchez NA, Catarino-Dircio A: [Bowen's disease of the breast]. Cir Cir; 2005 Sep-Oct;73(5):379-81
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bowen's disease of the breast].
  • [Transliterated title] Enfermedad de Bowen en la epidermis de la mama.
  • The patient was submitted to surgical resection with the presumptive diagnosis of Bowen's disease.
  • The histopathological report confirmed a squamous cell carcinoma in situ.
  • CONCLUSION: Epidermal Bowen's disease of breast is an uncommon entity but with similar clinical signs as in other anatomical areas.
  • [MeSH-major] Bowen's Disease. Skin Neoplasms

  • Genetic Alliance. consumer health - Bowen's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16336803.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Number-of-references] 11
  •  go-up   go-down


62. Brasanac D, Boricic I, Todorovic V, Tomanovic N, Radojevic S: Cyclin A and beta-catenin expression in actinic keratosis, Bowen's disease and invasive squamous cell carcinoma of the skin. Br J Dermatol; 2005 Dec;153(6):1166-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin A and beta-catenin expression in actinic keratosis, Bowen's disease and invasive squamous cell carcinoma of the skin.
  • BACKGROUND: Actinic keratosis (AK) has been defined as a precancerous lesion or an early phase in the evolution of squamous cell carcinoma (SCC) and histological changes seen in the individual cells of an AK are indistinguishable from those seen in SCC, which invade the dermis.
  • Cyclin A is an increasingly utilized proliferation marker that has functions in both S phase (DNA replication) and initiation of mitosis, whereas alterations of beta-catenin, the molecule involved in cell-cell adhesion and in signalling transduction, could promote invasive and proliferative capacities of malignant tumours.
  • OBJECTIVES: To determine cyclin A and beta-catenin expression pattern in cutaneous SCC and in in situ lesions classified as keratinocytic intraepidermal neoplasia (KIN) and, using traditional terms, as AK and Bowen's disease (BD), and to analyse it in relation to SCC differentiation, diameter and thickness.
  • On histological examination, 53 lesions were diagnosed as AK, 16 as BD and 41 as SCC-11 well differentiated (WD), 16 moderately differentiated (MD) and 14 poorly differentiated (PD).
  • RESULTS: Diffuse cyclin A presence was observed more frequently in BD than in AK (P < 0.0001) or SCC (P = 0.0002), and in SCC-PD compared with SCC-WD (P < 0.0001) or SCC-MD (P = 0.0003).
  • Cyclin A LI was significantly lower (P < 0.05) in AK than in BD or SCC, but no difference between BD and SCC was found, and LI in BD was even higher than in SCC-WD or SCC-MD, while analysis regarding SCC differentiation and KIN classification revealed the same correlation as for the cyclin A distribution.
  • Reduced or absent beta-catenin membranous staining was found in 90 cases (81.8%), more often in SCC than in AK (P = 0.03) or in AK and BD grouped together (P = 0.02).
  • Diffuse loss of membranous beta-catenin staining showed 36 lesions (32.7%), more frequently SCC than AK (P = 0.003) or AK and BD grouped (P = 0.006), as well as SCC-PD compared with SCC-WD (P = 0.01) and SCC-MD (P = 0.03), whereas all KIN comparisons remained nonsignificant.
  • Aberrant beta-catenin cellular localization demonstrated 28 lesions (25.5%), most often in the basal or peripheral parts and in the lesions with diffuse beta-catenin loss (P = 0.009), but revealed no correlation with the histological type, SCC level of differentiation or KIN grades.
  • Diffuse loss of membranous beta-catenin staining was found to be significantly more frequent in SCC thicker than 4 mm (P = 0.03), while all other comparisons between cyclin A or beta-catenin with the tumour size remained nonsignificant.
  • CONCLUSIONS: Cyclin A LI showed greater difference between AK and BD than between BD and SCC, suggesting that increased proliferation (measured by cyclin A LI) characterizes progression of in situ lesions from AK to BD, whereas reduced beta-catenin expression separates more clearly SCC from the in situ lesions.
  • Diffuse pattern of loss of membranous beta-catenin staining correlated better with the type of lesion, SCC differentiation and tumour size than reduced expression in general or aberrant cellular localization of beta-catenin.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Cyclin A / metabolism. Keratosis / metabolism. Skin Neoplasms / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bowen's Disease / metabolism. Bowen's Disease / pathology. Disease Progression. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Proteins / metabolism. Precancerous Conditions / metabolism. Precancerous Conditions / pathology


63. Quigley BC, Ricciuti J, Morgan MB: Amyloid light chain deposition associated with dermatofibroma: serendipity or association? Am J Dermatopathol; 2010 May;32(3):298-300
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary cutaneous amyloidosis, also known as nodular amyloidosis, is defined as deposition of amyloid light chain in the skin in the absence of a systemic cause of amyloidosis.
  • In contrast, secondary cutaneous amyloidosis is related to lesions such as squamous cell carcinoma, Bowen disease, basal cell carcinoma, and discoid lupus erythematosus, and has been shown in most cases to be derived from keratin epithelial elements.
  • [MeSH-major] Amyloid / metabolism. Histiocytoma, Benign Fibrous / pathology. Immunoglobulin Light Chains / metabolism. Skin Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Lipoma / diagnosis. Male. Middle Aged

  • Genetic Alliance. consumer health - Dermatofibroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20110798.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid; 0 / Immunoglobulin Light Chains
  •  go-up   go-down


64. Campbell SM, Morton CA, Alyahya R, Horton S, Pye A, Curnow A: Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma. Br J Dermatol; 2008 Aug;159(2):387-93
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma.
  • BACKGROUND: Photodynamic therapy (PDT) involves the activation of a photosensitizer by visible light to produce activated oxygen species within target cells, resulting in their destruction.
  • Evidence-based guidelines support the efficacy of PDT using topical 5-aminolaevulinic acid (ALA-PDT) in actinic keratoses, Bowen disease and basal cell carcinoma (BCC).
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Iron Chelating Agents / therapeutic use. Photochemotherapy / methods. Pyridones / therapeutic use. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Dermatol. 2009 Jul;161(1):215-6 [19438852.001]
  • (PMID = 18544077.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iron Chelating Agents; 0 / Photosensitizing Agents; 0 / Pyridones; 115900-75-9 / 1,2-diethyl-3-hydroxypyridin-4-one; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


65. Aractingi S, Kanitakis J, Euvrard S, Le Danff C, Peguillet I, Khosrotehrani K, Lantz O, Carosella ED: Skin carcinoma arising from donor cells in a kidney transplant recipient. Cancer Res; 2005 Mar 1;65(5):1755-60
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin carcinoma arising from donor cells in a kidney transplant recipient.
  • The incidence of skin cancer is increased in transplant recipients.
  • Herein, we investigated the possible involvement of donor cells in the development of skin tumors in kidney allograft recipients.
  • Male cells were detected in 5/15 squamous cell carcinomas and Bowen disease (range 4-180 copies), 3/5 basal cell carcinomas (91-645), 6/11 actinic keratosis (7-102), 2/4 keratoacanthoma (22-41), and 2/5 benign cutaneous lesions (14-55).
  • In a basal cell carcinoma specimen with a high number of male cells, FISH showed that most cells within the tumoral buds were XY.
  • In conclusion, stem cells originating from a grafted kidney may migrate to the skin, differentiate, or fuse as keratinocytes that could, rarely, undergo cancer transformation.
  • [MeSH-major] Kidney Transplantation / adverse effects. Skin Diseases / etiology. Skin Neoplasms / etiology. Stem Cells / pathology. Tissue Donors
  • [MeSH-minor] Bowen's Disease / etiology. Carcinoma, Basal Cell / etiology. Carcinoma, Squamous Cell / etiology. Cell Differentiation. Cell Fusion. Chromosomes, Human, X / genetics. Chromosomes, Human, Y / genetics. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Karyotyping. Keratinocytes / cytology. Keratinocytes / metabolism. Keratins / metabolism. Keratoacanthoma / etiology. Keratosis / etiology. Male. Reverse Transcriptase Polymerase Chain Reaction. Transplantation, Homologous


66. Blum A, Hartmann KW, Rütten A: [Brownish coloration of the left nipple in a 60-year-old woman]. Hautarzt; 2010 Jan;61(1):64-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pigmented Paget disease of the nipple is a rare disease.
  • We report on a 60-year-old woman in whom this diagnosis was made based on clinical findings, dermoscopy, histology and immunohistology.
  • Dermoscopy can enhance the clinical diagnosis.
  • On histology, rare melanocytic tumors must be differentiated from pigmented Paget disease and pigmented Bowen disease.
  • Pagetoid intraepithelial cells of a melanocytic tumor are positive for S100, HMB45 or melan A, but not for cytokeratins.
  • Intraepithelial tumor cells of Paget disease are positive for cytokeratin 7.
  • The clear cells in Bowen diseases are usually not positive for cytokeratin 7 and are also negative for all melanocytic markers.
  • [MeSH-major] Erythema / diagnosis. Erythema / etiology. Nipples / pathology. Paget's Disease, Mammary / complications. Paget's Disease, Mammary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast J. 2009 Jul-Aug;15(4):420-1 [19470138.001]
  • [Cites] Am J Dermatopathol. 2002 Jun;24(3):189-98 [12140433.001]
  • [Cites] Br J Dermatol. 1998 Aug;139(2):287-90 [9767245.001]
  • [Cites] J Am Acad Dermatol. 1994 Dec;31(6):1058-60 [7962760.001]
  • [Cites] Radiographics. 2009 Mar-Apr;29(2):509-23 [19325062.001]
  • [Cites] J Am Acad Dermatol. 2004 Oct;51(4):664-5 [15455482.001]
  • [Cites] Dermatol Surg. 2006 Jul;32(7):949-54 [16875480.001]
  • [Cites] Histopathology. 2009 Apr;54(5):614-7 [19413640.001]
  • [Cites] Dermatology. 2007;214(1):3-5 [17191039.001]
  • [Cites] Arch Dermatol. 2007 Jun;143(6):752-4 [17576941.001]
  • [Cites] Am J Dermatopathol. 2009 May;31(3):223-6 [19384061.001]
  • [Cites] Dermatol Surg. 2008 Aug;34(8):1101-3 [18462414.001]
  • [Cites] Clin Exp Dermatol. 2009 Jan;34(1):36-8 [18627392.001]
  • [Cites] Hautarzt. 1992 Jan;43(1):28-31 [1319418.001]
  • [Cites] J Am Acad Dermatol. 2002 Mar;46(3):414-8 [11862178.001]
  • (PMID = 19967329.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


67. Hansen JP, Drake AL, Walling HW: Bowen's Disease: a four-year retrospective review of epidemiology and treatment at a university center. Dermatol Surg; 2008 Jul;34(7):878-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowen's Disease: a four-year retrospective review of epidemiology and treatment at a university center.
  • BACKGROUND: Cutaneous squamous cell carcinoma (SCC) in situ (Bowen's disease;.
  • BD) is a common intraepidermal malignancy.
  • The aim of this study was to characterize the demographics, distribution, treatment, and recurrence risk of BD in a university population.
  • METHODS: A retrospective survey of histologically confirmed BD diagnosed between January 1999 and January 2003.
  • RESULTS: A total of 299 patients (193 men, 106 women) with 406 cases of BD were identified.
  • Men were significantly more likely to have SCC in situ on the scalp, ear, and anterior trunk, while the cheek, nose, and lower legs were significantly more common sites among women (p<.05).
  • Histologic recurrence was seen in 15 of 406 cases (4%), one of which recurred as invasive SCC.
  • LIMITATIONS: Our experience at a single institution in the midwestern United States may not be reflective of a wider population.
  • CONCLUSION: The most common locations for BD were in areas with high sun exposure.
  • [MeSH-major] Bowen's Disease / epidemiology. Bowen's Disease / therapy. Skin Neoplasms / epidemiology. Skin Neoplasms / therapy

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363722.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Tsai TM, Wu YH, Yang KC, Yang CY, Tsai TH, Chan JY: Sebaceous carcinoma associated with seborrheic keratosis. J Cutan Med Surg; 2010 Sep-Oct;14(5):240-4
Genetic Alliance. consumer health - Keratosis, seborrheic.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sebaceous carcinoma associated with seborrheic keratosis.
  • BACKGROUND: The association of a seborrheic keratosis with other common cutaneous neoplasms such as basal cell carcinoma and Bowen disease has been reported, but the association between a seborrheic keratotis and a malignant neoplasm with sebaceous differentiation is very unusual.
  • OBJECTIVE: We present a case of two contiguous neoplasms, a seborrheic keratosis and a sebaceous carcinoma, and discuss the possibility of malignant change in a seborrheic keratosis as an explanation for the findings.
  • METHODS AND RESULTS: A 57-year-old man presented with an asymptomatic tumor on the skin of his abdomen that was composed of two separate but contiguous lesions.
  • Histopathologic examination revealed that the plaque was composed of two different adjacent tumors, including a central portion showing findings consistent with a sebaceous carcinoma and a peripheral part showing a seborrheic keratosis.
  • CONCLUSION: Although the association is likely to be a coincidence and probably represents a collision tumor, the possibility that the sebaceous carcinoma represents malignant degeneration of the seborrheic keratosis cannot be entirely excluded.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20868621.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


69. Kessler GM, Ackerman AB: Nomenclature for very superficial squamous cell carcinoma of the skin and of the cervix: a critique in historical perspective. Am J Dermatopathol; 2006 Dec;28(6):537-45
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nomenclature for very superficial squamous cell carcinoma of the skin and of the cervix: a critique in historical perspective.
  • Squamous-cell carcinoma is the most common of all cancers and it develops in diverse organs of the body, among those being the skin, lung, gastrointestinal tract, and genitourinary tract, the latter including the cervix.
  • Unfortunately, no unanimity exists for naming very superficial squamous-cell carcinoma; it has not been designated in consistent fashion in a single organ, let alone in all of them, thereby resulting in confusion, not only in regard to terminology per se, but concerning matters conceptual, not the least of those being what appellation to apply to that condition when it is encountered histopathologically.
  • This vexing situation is illustrated graphically in the skin by diagnoses for very superficial squamous-cell carcinoma as disparate as solar keratosis (actinic keratosis, senile keratosis), arsenical keratosis, radiation keratosis, Bowen disease, bowenoid papulosis, squamous-cell carcinoma in situ, as well as variations on the theme of "keratinocytic intraepidermal neoplasia" and "dysplasia," and in the cervix by squamous-cell carcinoma in situ, leukoplakia, cervical intraepithelial neoplasia I-III, as well as variations on the theme of "squamous dysplasia ()."
  • There is a need urgently for a single term for very superficial squamous-cell carcinoma in every organ of the body in which it develops, to wit, one that conveys diagnosis in such logical, lucid, comprehensible fashion that it is understandable, readily and immediately, to clinicians.
  • [MeSH-major] Carcinoma, Squamous Cell / classification. Skin Neoplasms / classification. Uterine Cervical Neoplasms / classification

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122500.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Cohen PR, Schulze KE, Rady PL, Tyring SK, He Q, Martinelli PT, Nelson BR: Coincidental consort clear cell cutaneous carcinoma: facial squamous cell carcinoma in situ containing human papillomavirus and cancer cells with clear cytoplasm in an octogenarian couple. South Med J; 2007 May;100(5):525-30
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coincidental consort clear cell cutaneous carcinoma: facial squamous cell carcinoma in situ containing human papillomavirus and cancer cells with clear cytoplasm in an octogenarian couple.
  • Clear cell squamous cell carcinoma in situ, also referred to as pagetoid or clear cell Bowen disease, is a rare pathologic variant of this neoplasm.
  • An octogenarian husband and wife concurrently developed new facial skin lesions which demonstrated squamous cell carcinoma in situ consisting of cancer cells with clear cytoplasm.
  • Cutaneous human papillomavirus (HPV) typing detected HPV Type 5 and HPV Type 21 in the tumors of the husband and wife, respectively.
  • HPV is a potential etiologic factor in the oncogenesis of nonmelanoma skin cancer, and HPV DNA has been demonstrated in extragenital squamous cell carcinoma in situ.
  • The detection of DNA from different HPV types in the tumors of our patients suggests that the concurrent occurrence of their skin cancers may have been coincidental.
  • However, the presence of HPV DNA in their tumors introduces the possibility of a viral-associated oncogenesis for clear cell squamous cell carcinoma in situ.
  • [MeSH-major] Bowen's Disease / virology. Carcinoma in Situ / virology. Facial Neoplasms / virology. Papillomaviridae / isolation & purification. Skin Neoplasms / virology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Facial Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17534094.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Vinh DC, Patel SY, Uzel G, Anderson VL, Freeman AF, Olivier KN, Spalding C, Hughes S, Pittaluga S, Raffeld M, Sorbara LR, Elloumi HZ, Kuhns DB, Turner ML, Cowen EW, Fink D, Long-Priel D, Hsu AP, Ding L, Paulson ML, Whitney AR, Sampaio EP, Frucht DM, DeLeo FR, Holland SM: Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood; 2010 Feb 25;115(8):1519-29
SciCrunch. OMIM: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten of these patients developed 1 or more of the following malignancies: 9 myelodysplasia/leukemia, 1 vulvar carcinoma and metastatic melanoma, 1 cervical carcinoma, 1 Bowen disease of the vulva, and 1 multiple Epstein-Barr virus(+) leiomyosarcoma.

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • MedlinePlus Health Information. consumer health - Genetic Disorders.
  • MedlinePlus Health Information. consumer health - Mycobacterial Infections.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 2007 Apr;26(4):390-2 [17459807.001]
  • [Cites] Pathol Biol (Paris). 2007 Feb;55(1):37-48 [16697122.001]
  • [Cites] Immunol Res. 2007;38(1-3):342-6 [17917041.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6816-28 [17934488.001]
  • [Cites] Curr Treat Options Oncol. 2007 Apr;8(2):129-34 [17926010.001]
  • [Cites] Annu Rev Pathol. 2006;1:375-404 [18039120.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1350-7 [18042691.001]
  • [Cites] Br J Haematol. 2008 Jan;140(2):123-32 [18173751.001]
  • [Cites] Curr Opin Immunol. 2008 Feb;20(1):52-60 [18160272.001]
  • [Cites] Am J Respir Cell Mol Biol. 2008 Apr;38(4):380-5 [18192503.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Apr 1;177(7):752-62 [18202348.001]
  • [Cites] Blood. 2008 May 15;111(10):4841-51 [18467609.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):66-70 [18085671.001]
  • [Cites] Immunol Invest. 2008;37(5):467-81 [18716934.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7693-706 [18829521.001]
  • [Cites] J Allergy Clin Immunol. 2008 Dec;122(6):1043-51; quiz 1052-3 [19084105.001]
  • [Cites] Virology. 2009 Feb 20;384(2):260-5 [19135222.001]
  • [Cites] PLoS One. 2009;4(4):e5210 [19381294.001]
  • [Cites] Clin Infect Dis. 2009 Jul 1;49(1):102-11 [19489714.001]
  • [Cites] Science. 1976 Jun 4;192(4243):1016-8 [775638.001]
  • [Cites] Clin Immunol. 2000 May;95(2):85-92 [10779401.001]
  • [Cites] Immunol Lett. 2000 May 1;72(2):75-82 [10841941.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):658-62 [10934102.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1107-11 [11323675.001]
  • [Cites] J Infect. 2001 Apr;42(3):213-4 [11545557.001]
  • [Cites] Leuk Res. 2002 Jun;26(6):591-5 [12007507.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Jul 15;166(2):215-35 [12119235.001]
  • [Cites] Front Biosci. 2002 Oct 1;7:d2058-71 [12165480.001]
  • [Cites] Microbes Infect. 2002 Dec;4(15):1545-58 [12505527.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Mar;16(1):33-40 [12670463.001]
  • [Cites] Thorax. 2003 Jul;58(7):645 [12832691.001]
  • [Cites] Am J Hematol. 2003 Nov;74(3):221-3 [14587059.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jan 15;148(2):155-8 [14734230.001]
  • [Cites] J Pediatr. 2004 Apr;144(4):519-23 [15069403.001]
  • [Cites] Stem Cells. 2004;22(4):590-9 [15277704.001]
  • [Cites] Immunity. 2004 Aug;21(2):137-48 [15308095.001]
  • [Cites] Am J Kidney Dis. 2004 Sep;44(3):556-8 [15332229.001]
  • [Cites] J Exp Med. 1978 Jul 1;148(1):1-17 [670884.001]
  • [Cites] Science. 1978 Sep 8;201(4359):937-8 [356266.001]
  • [Cites] Blood. 1979 Mar;53(3):412-36 [367468.001]
  • [Cites] Lab Invest. 1982 Feb;46(2):165-70 [6174824.001]
  • [Cites] Cancer. 1982 May 1;49(9):1924-8 [7074589.001]
  • [Cites] Scand J Haematol. 1982 Aug;29(2):153-60 [6753123.001]
  • [Cites] J Exp Med. 1984 Nov 1;160(5):1273-83 [6491600.001]
  • [Cites] J Leukoc Biol. 1987 Nov;42(5):443-6 [3316460.001]
  • [Cites] J Allergy Clin Immunol. 1990 Feb;85(2):453-9 [2303649.001]
  • [Cites] Lancet. 1992 Sep 19;340(8821):731 [1355830.001]
  • [Cites] N Engl J Med. 1994 May 12;330(19):1348-55 [7908719.001]
  • [Cites] Respir Med. 1996 Nov;90(10):641-2 [8959124.001]
  • [Cites] J Clin Invest. 1997 Nov 1;100(9):2211-7 [9410898.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61 [9636188.001]
  • [Cites] J Exp Med. 1999 Sep 20;190(6):875-80 [10499925.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2521-5 [15621772.001]
  • [Cites] J Immunol. 2005 Oct 1;175(7):4769-76 [16177125.001]
  • [Cites] Am J Hum Genet. 2006 Apr;78(4):721-7 [16532402.001]
  • [Cites] Genes Dev. 2006 Nov 1;20(21):3010-21 [17079688.001]
  • [Cites] J Infect Chemother. 2006 Oct;12(5):331-4 [17109096.001]
  • [Cites] J Immunol. 2007 Feb 15;178(4):2000-7 [17277103.001]
  • [Cites] J Immunol. 2007 Sep 15;179(6):3488-94 [17785782.001]
  • (PMID = 20040766.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / ; Canada / Canadian Institutes of Health Research / / ; United States / NCI NIH HHS / CA / N01CO12400; United States / CCR NIH HHS / RC / HHSN261200800001C; United States / NCI NIH HHS / CO / N01-CO-12400; United States / NCI NIH HHS / CA / HHSN261200800001E
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2830758
  •  go-up   go-down


72. Graham BD, Jetmore AB, Foote JE, Arnold LK: Topical 5-fluorouracil in the management of extensive anal Bowen's disease: a preferred approach. Dis Colon Rectum; 2005 Mar;48(3):444-50
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical 5-fluorouracil in the management of extensive anal Bowen's disease: a preferred approach.
  • PURPOSE: An alternative approach to anal Bowen's disease was investigated.
  • METHODS: A prospective study was undertaken for anal Bowen's disease in 11 patients over a six-year period.
  • For one-half circumferential disease or greater, patients underwent topical 5 percent 5-fluorouacil therapy for 16 weeks.
  • Three patients (3 female) underwent surgical excision for localized disease.
  • All but one patient, who was HIV positive, were free of Bowen's disease one year after completion of therapy.
  • One patient underwent total excision of a residual microinvasive squamous carcinoma after circumferential Bowen's disease had resolved.
  • CONCLUSION: Topical 5 percent 5-fluorouacil therapy is a safe and effective method to treat anal Bowen's disease.
  • Wide local excision is appropriate for smaller, isolated areas of disease.
  • Anal Bowen's disease was not associated with colonic or other neoplasms.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Anus Neoplasms / drug therapy. Bowen's Disease / drug therapy. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15747068.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


73. Prior SL, Griffiths AP, Lewis PD: A study of mitochondrial DNA D-loop mutations and p53 status in nonmelanoma skin cancer. Br J Dermatol; 2009 Nov;161(5):1067-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of mitochondrial DNA D-loop mutations and p53 status in nonmelanoma skin cancer.
  • BACKGROUND: Mitochondrial DNA (mtDNA) displacement-loop (D-loop) mutations have previously demonstrated potential as smoking-induced biomarkers in oral squamous cell carcinoma (SCC).
  • Additionally, they have been observed in SCC and basal cell carcinoma of nonmelanoma skin cancer (NMSC).
  • However, they have not been examined in the SCC precursor lesions, Bowen disease or actinic keratosis.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. DNA, Mitochondrial / genetics. Mutation. Skin Neoplasms / genetics. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction. Sequence Analysis, DNA. Skin Diseases / genetics. Skin Diseases / metabolism. Smoking

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19624548.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


74. Kamiya H, Kitajima Y, Ban M: Bowen's disease with invasive adnexal carcinoma: the pluripotential nature of Bowen's disease cells. J Dermatol; 2006 Dec;33(12):858-64
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowen's disease with invasive adnexal carcinoma: the pluripotential nature of Bowen's disease cells.
  • Bowen's disease rarely exhibits multiple combinations of premalignant and/or malignant skin lesions.
  • Bowen's disease with invasive adnexal carcinoma was originally described by Kao, but is not well recognized by clinicians due to its rarity and lack of specific clinical features of this condition.
  • Herein, we describe three unusual cases of Bowen's disease with invasive adnexal carcinoma.
  • The plaque lesions possessed clinical features typical of Bowen's disease.
  • In cases 1 and 3, we confirmed the adnexal tumor within tumors of Bowen's disease, the diagnosis of which is eccrine porocarcinoma.
  • The tumor in case 2 was characteristic to trichilemmal carcinoma.
  • Immunohistochemically, the tumor cells of Bowen's disease and the adnexal carcinoma differed in antigenicities.
  • The present cases support a notion that Bowen's disease maintains a pluripotential nature.
  • [MeSH-major] Bowen's Disease / pathology. Carcinoma, Skin Appendage / pathology. Cell Transformation, Neoplastic / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Acrospiroma / pathology. Aged. Aged, 80 and over. Female. Humans. Neoplasm Invasiveness. Neoplasms, Basal Cell / pathology

  • Genetic Alliance. consumer health - Bowen's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17169090.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


75. Pfaff D, Philippova M, Buechner SA, Maslova K, Mathys T, Erne P, Resink TJ: T-cadherin loss induces an invasive phenotype in human keratinocytes and squamous cell carcinoma (SCC) cells in vitro and is associated with malignant transformation of cutaneous SCC in vivo. Br J Dermatol; 2010 Aug;163(2):353-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cadherin loss induces an invasive phenotype in human keratinocytes and squamous cell carcinoma (SCC) cells in vitro and is associated with malignant transformation of cutaneous SCC in vivo.
  • Atypical glycosylphosphatidylinositol-anchored T-cadherin (T-cad) is highly expressed in the basal keratinocyte layer of skin.
  • OBJECTIVES: To define the role of T-cad in the pathogenesis of cutaneous squamous cell carcinoma (SCC) through gain-of-function and loss-of-function studies in vitro and through examination of T-cad expression patterns in human cutaneous SCC specimens in relation to histological classification of degree of tumour differentiation.
  • METHODS: In vitro studies employed lentiviral-mediated overexpression/silencing of T-cad in normal human keratinocyte (HaCaT) and SCC (A431) cell lines, monolayer and multicellular spheroid culture models, cell morphology analyses and assays of random motility and invasion.
  • Immunohistochemistry was performed on skin specimens from patients with actinic keratosis, Bowen disease or SCC.
  • RESULTS: In vitro, silencing of T-cad induced a morphologically elongated and disorganized cell phenotype, increased random motility and markedly enhanced invasive potential.
  • Overexpression of T-cad induced a morphologically spread and compact cell phenotype and blunted invasive potential.
  • In vivo, regional loss of T-cad expression was more frequent and prominent in SCC classified as moderately-to-poorly differentiated than in SCC classified as well differentiated.
  • However, in both categories aberrant and/or absence of T-cad expression was associated with histological features of a potentially more malignant and invasive phenotype of cutaneous SCC.
  • CONCLUSIONS: T-cad is a controlling determinant of SCC phenotype and invasive behaviour and its loss is associated with the process of malignant transformation from noninvasive to invasive SCC.
  • [MeSH-major] Cadherins / physiology. Carcinoma, Squamous Cell / pathology. Cell Transformation, Neoplastic / pathology. Keratinocytes / pathology. Neoplasm Proteins / physiology. Skin Neoplasms / pathology
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Cell Migration Assays. Fluorescent Antibody Technique. Gene Silencing. Humans. Neoplasm Invasiveness / physiopathology. Phenotype. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20394625.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / H-cadherin; 0 / Neoplasm Proteins
  •  go-up   go-down


76. Ständer S, Schwarz T: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is expressed in normal skin and cutaneous inflammatory diseases, but not in chronically UV-exposed skin and non-melanoma skin cancer. Am J Dermatopathol; 2005 Apr;27(2):116-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is expressed in normal skin and cutaneous inflammatory diseases, but not in chronically UV-exposed skin and non-melanoma skin cancer.
  • Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is a member of the tumor necrosis factor family that preferentially induces apoptosis in transformed but not normal cells and that is constitutively expressed in many organs including the skin.
  • Therefore, we studied the effect of UV exposure on the expression of TRAIL in the skin by immunohistochemical analysis.
  • TRAIL and its receptors TRAIL-R1 and TRAIL-R4 were constitutively expressed in normal epidermis and not altered in a variety of inflammatory dermatoses including those associated with interface dermatitis.
  • No differences were observed in UV-protected and chronically UV-exposed skin samples of younger adults.
  • In contrast, TRAIL was significantly reduced in chronically UV-exposed skin of elderly individuals.
  • In addition, TRAIL expression was reduced in actinic keratoses and Bowen disease and almost completely lost in basal cell and squamous cell carcinomas.
  • Taken together, these data indicate that chronic UV exposure in elderly patients results in the loss of TRAIL expression, which might contribute to the increased risk of skin cancer in this population.
  • Down-regulation of TRAIL might represent another example of a natural protection mechanism that is eliminated by chronic UV exposure.
  • [MeSH-major] Inflammation / metabolism. Membrane Glycoproteins / biosynthesis. Skin / metabolism. Skin Neoplasms / metabolism. Tumor Necrosis Factor-alpha / biosynthesis
  • [MeSH-minor] Adult. Aged. Apoptosis Regulatory Proteins. Humans. Immunohistochemistry. Middle Aged. Receptors, TNF-Related Apoptosis-Inducing Ligand. Receptors, Tumor Necrosis Factor / biosynthesis. Receptors, Tumor Necrosis Factor / radiation effects. Skin Diseases / pathology. TNF-Related Apoptosis-Inducing Ligand. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15798435.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Membrane Glycoproteins; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10A protein, human; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


77. Menzies SW, Emery J, Staples M, Davies S, McAvoy B, Fletcher J, Shahid KR, Reid G, Avramidis M, Ward AM, Burton RC, Elwood JM: Impact of dermoscopy and short-term sequential digital dermoscopy imaging for the management of pigmented lesions in primary care: a sequential intervention trial. Br J Dermatol; 2009 Dec;161(6):1270-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Studies have shown the benign to malignant ratio of excised pigmented skin lesions is suboptimal in primary care.
  • OBJECTIVES: To assess the impact of dermoscopy and short-term sequential digital dermoscopy imaging (SDDI) on the management of suspicious pigmented skin lesions by primary care physicians.
  • They were then given a dermatoscope and the option of a SDDI instrument, and change of diagnosis and management was assessed.
  • Of the 42 malignant lesions included in the study (34 melanoma, six pigmented basal cell carcinoma and two Bowen disease) only one in situ melanoma was incorrectly managed (patient to return if changes occur) resulting in the correct management of 97.6% and 97.1% of malignant pigmented lesions and melanoma, respectively.
  • CONCLUSIONS: In a primary care setting the combination of dermoscopy and short-term SDDI reduces the excision or referral of benign pigmented lesions by more than half while nearly doubling the sensitivity for the diagnosis of melanoma.
  • [MeSH-major] Dermoscopy / methods. Early Detection of Cancer / methods. Melanoma / diagnosis. Physical Examination / methods. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Health Checkup.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19747359.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


78. Nagai Y, Ishibuchi H, Takahashi M, Shimizu A, Matsushima Y, Tamura A, Ishikawa O: Extramammary Paget's disease with bowenoid histologic features accompanied by an ectopic lesion on the upper abdomen. J Dermatol; 2005 Aug;32(8):670-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramammary Paget's disease with bowenoid histologic features accompanied by an ectopic lesion on the upper abdomen.
  • We present a 79-year-old man who suffered from extramammary Paget's disease (EMPD) with bowenoid histological features accompanied by an ectopic EMPD lesion on his abdomen.
  • Based on a biopsy specimen, he was referred to our hospital with the histological diagnosis of Bowen's disease.
  • The histological findings of the genital lesion obtained by surgical resection showed typical areas of Paget's cells adjacent to areas characteristic of Bowen's disease.
  • Immunohistochemical findings showed CEA and CK7 positive tumor cells in both areas, so the atypical cells showing the bowenoid pattern could be regarded as tumor cells of Paget's disease.
  • Immunohistochemical staining for CEA and CK7 along with multiple biopsies can be helpful in making the diagnosis of Paget's disease with bowenoid histologic features.
  • [MeSH-major] Bowen's Disease / diagnosis. Paget Disease, Extramammary / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Abdomen. Aged. Diagnosis, Differential. Genitalia, Male / pathology. Humans. Immunohistochemistry. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334870.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


79. Perrin C, Baran R, Balaguer T, Chignon-Sicard B, Cannata GE, Petrella T, Michiels JF: Onychomatricoma: new clinical and histological features. A review of 19 tumors. Am J Dermatopathol; 2010 Feb;32(1):1-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The characteristic histologic appearance of OM is sometimes difficult to grasp because of 3 main factors: the anatomic particularities of the nail apparatus, the often fragmented aspect of the tissue specimen, and the choice of the section planes, which strongly modified the morphologic appearances observed.
  • This reconstitution gives us a better understanding of the apparent diversity of the morphologic aspects observed in linking them to the anatomic site of the tumor.
  • We individualize 3 misleading clinical variants: tumor with a verrucous surface that is located in the lateral nail fold, as a band pattern suggesting wart or Bowen disease; a total dystrophy of the nail unit mimicking a squamous cell carcinoma; and pseudofibrokeratoma type.
  • OM is a benign tumor with a broader morphologic spectrum than previously thought.
  • When the nail plate is not available, the immunohistochemistry can aid diagnosis by highlighting the peculiar immunophenotyping of OM, which expresses CD34 but not CD99, epithelial membrane antigen, S-100 protein, actin, and desmin.
  • [MeSH-major] Nail Diseases / pathology. Nails, Malformed / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Bowen's Disease / diagnosis. Carcinoma, Squamous Cell / diagnosis. Diagnosis, Differential. Female. Fibroma / diagnosis. Humans. Imaging, Three-Dimensional / methods. Immunohistochemistry. Male. Middle Aged. Models, Anatomic. Warts / diagnosis. Young Adult

  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098079.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


80. Ortiz-Policarpio B, Lui H: Methyl aminolevulinate-PDT for actinic keratoses and superficial nonmelanoma skin cancers. Skin Therapy Lett; 2009 Jul-Aug;14(6):1-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methyl aminolevulinate-PDT for actinic keratoses and superficial nonmelanoma skin cancers.
  • Methyl aminolevulinate-hydrochloride cream (Metvix [in Canada] and Metvixia [in the US], Galderma) in combination with photodynamic therapy (PDT) provides an effective treatment option for actinic keratoses (AKs), superficial basal cell carcinoma (sBCC), and Bowen's disease (BD).
  • In BD, CR rates were 93% at 3 months and 68% at 2 years.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Keratosis, Actinic / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Combined Modality Therapy. Humans. Treatment Outcome. Ultraviolet Rays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19609473.001).
  • [ISSN] 1201-5989
  • [Journal-full-title] Skin therapy letter
  • [ISO-abbreviation] Skin Therapy Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 20
  •  go-up   go-down


81. Legoupil D, Lemasson G, Davaine AC, Misery L: [Bowen's disease and squamous cell carcinoma in Haber's syndrome: two cases]. Ann Dermatol Venereol; 2007 Jan;134(1):59-61
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bowen's disease and squamous cell carcinoma in Haber's syndrome: two cases].
  • [Transliterated title] Maladie de Bowen et carcinome épidermoïde au cours d'un syndrome de Haber: deux cas.
  • We report two cases of Bowen's disease and cutaneous epidermoid carcinoma in Haber's syndrome patients.
  • OBSERVATIONS: A 67 year-old woman with Haber's syndrome and with a familial history consulted for a budding lesion on the abdomen, histological examination of which confirmed epidermoid carcinoma.
  • Histological examination of a biopsy sample confirmed the clinical diagnosis of Bowen's disease.
  • Association with skin carcinomas requires regular monitoring of these patients.
  • The use of imiquimod to treat lesions in patients with Bowen's disease resulted in complete cure.
  • [MeSH-major] Bowen's Disease / complications. Carcinoma, Squamous Cell / complications. Keratosis / complications. Neoplasms, Multiple Primary / complications. Rosacea / complications. Skin Neoplasms / complications

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Rosacea.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17384546.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


82. Yahya H, Mohammed A: Bowen's disease: report of a case in a Nigerian man. West Afr J Med; 2005 Oct-Dec;24(4):350-1
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowen's disease: report of a case in a Nigerian man.
  • Bowen's disease (cutaneous squamous cell carcinoma in situ), like other cancers of the skin, is rare in black people--to our knowledge, only about 43 cases have been published in the medical literature.
  • We report a 59-year old Nigerian man who presented with a five-year history of a mildly pruritic, slowly enlarging well-circumscribed plaque on the lower part of the anterior region of the chest on the right side.
  • Histological examination confirmed a diagnosis of Bowen's disease.
  • No predisposing factor was found to be relevant in this case--although he might have had brief occupational exposure to arsenic, it is unlikely that this was the cause of his disease.
  • The published literature on Bowen's disease in blacks is briefly reviewed.
  • [MeSH-major] Bowen's Disease / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] African Continental Ancestry Group. Carcinoma in Situ / diagnosis. Humans. Male. Middle Aged. Pruritus. Thorax / physiopathology

  • Genetic Alliance. consumer health - Bowen's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16483058.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


83. Kacerovská D, Pizinger K, Majer F, Smíd F: Photodynamic therapy of nonmelanoma skin cancer with topical hypericum perforatum extract--a pilot study. Photochem Photobiol; 2008 May-Jun;84(3):779-85
Hazardous Substances Data Bank. PERYLENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of nonmelanoma skin cancer with topical hypericum perforatum extract--a pilot study.
  • However, there is only limited knowledge regarding the photodynamic effect of hypericin on nonmelanoma skin cancer cells.
  • The aim of this prospective study was to investigate the efficacy of photodynamic therapy with topical application of an extract of H. perforatum in actinic keratosis, basal cell carcinoma (BCC) and morbus Bowen (carcinoma in situ).
  • The study was carried out on 34 patients--eight with actinic keratoses (AKs), 21 with BCC and five with Bowen's disease.
  • The extract of H. perforatum was applied on the skin lesions under occlusion and that was followed by irradiation with 75 J cm(-2) of red light 2 h later.
  • The percentage of complete clinical response was 50% for AKs, 28% in patients with superficial BCC and 40% in patients with Bowen's disease.
  • A complete disappearance of tumor cells was found in the histologic preparation of 11% of patients with superficial BCCs and 80% in the patients with Bowen's disease.
  • [MeSH-major] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Hypericum. Perylene / analogs & derivatives. Photochemotherapy / methods. Plant Preparations / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179625.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Plant Preparations; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin
  •  go-up   go-down


84. Chen S, Takahara M, Kido M, Takeuchi S, Uchi H, Tu Y, Moroi Y, Furue M: Increased expression of an epidermal stem cell marker, cytokeratin 19, in cutaneous squamous cell carcinoma. Br J Dermatol; 2008 Sep;159(4):952-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of an epidermal stem cell marker, cytokeratin 19, in cutaneous squamous cell carcinoma.
  • Cumulative reports have shown that epidermal stem cells play an important role in skin carcinogenesis.
  • However, to date there has been no report on the clinical alteration of the stem cells in squamous cell carcinoma (SCC).
  • OBJECTIVES: To investigate alteration of the stem cells and proliferating cells and to assess their relationship and potential contribution to SCC.
  • METHODS: Thirty paraffin-embedded neoplastic skin lesions, consisting of 10 cases each of actinic keratosis (AK), Bowen disease (BD) and SCC, were examined immunohistologically for CK19 and Ki-67.
  • RESULTS: Positive reactivity for CK19 was seen in 30% of AK, 50% of BD and 80% of SCC lesions.
  • There was significantly higher expression levels of CK19 in SCC than in AK and BD (P < 0.05).
  • In addition, BD lesions harboured a significantly higher number of CK19-positive cells than did AK lesions (P < 0.05).
  • There were significant differences in Ki-67 labelling indices between AK and BD and between AK and SCC (P < 0.001), but not between BD and SCC (P > 0.05).
  • Furthermore, a serial section comparison study showed that there was a minor population of cells co-expressing CK19 and Ki-67 in a subset of the tumour cells of SCC samples.
  • The percentage of CK19+ cells significantly correlated with that of Ki67+ cells in all examined neoplastic skin lesions.
  • CONCLUSIONS: These results suggest that CK19 expression may be associated with the retention of stem cell characteristics or a state that is uncommitted to terminal squamous differentiation.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Epidermis / metabolism. Keratin-19 / metabolism. Skin Neoplasms / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18647309.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-19
  •  go-up   go-down


85. Moseley H, Ibbotson S, Woods J, Brancaleon L, Lesar A, Goodman C, Ferguson J: Clinical and research applications of photodynamic therapy in dermatology: experience of the Scottish PDT Centre. Lasers Surg Med; 2006 Jun;38(5):403-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVES: The Scottish PDT Centre has carried out 3,442 treatments on 762 patients with superficial skin lesions, especially superficial basal cell carcinoma (sBCC), Bowen's disease (BD) and actinic keratosis (AK).
  • CONCLUSIONS: In our experience, topical PDT is generally well tolerated and is an effective treatment of sBCC, BD, AK, field change and lesions at sites of poor healing.
  • [MeSH-major] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Keratosis / drug therapy. Photochemotherapy / methods. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16788933.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


86. Hida Y, Kubo Y, Arase S: Activation of fibroblast growth factor receptor 3 and oncogene-induced senescence in skin tumours. Br J Dermatol; 2009 Jun;160(6):1258-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of fibroblast growth factor receptor 3 and oncogene-induced senescence in skin tumours.
  • OBJECTIVES: The aim of this study was to examine the activation of fibroblast growth factor receptor 3 (FGFR3) as an oncogene product and OIS in human skin tumours.
  • METHODS: We investigated the activation of FGFR3 and OIS by mutation and immunohistochemical analysis in skin tumours, including seborrhoeic keratosis, actinic keratosis (AK), Bowen's disease (BD), basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • RESULTS: Activated point mutations of FGFR3 were identified in four of 22 cases (18%) of seborrhoeic keratosis, but no mutation was detected in the other skin tumours.
  • Twenty-seven of 31 cases (87%) of seborrhoeic keratosis showed moderately to strongly positive expression of the FGFR3 protein, but almost all the other skin tumours were negative.
  • Immunoreactivity for gamma-H2AX was significantly greater in AK than in seborrhoeic keratosis, BD, BCC and SCC.
  • In addition, OIS due to some oncogenic signals rather than activation of FGFR3 might be involved in the early skin carcinogenesis related to chronic ultraviolet radiation exposure.
  • [MeSH-major] Oncogenes / genetics. Receptor, Fibroblast Growth Factor, Type 3 / genetics. Skin Aging / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Bowen's Disease / genetics. Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Chi-Square Distribution. Humans. Keratosis, Actinic / genetics. Keratosis, Seborrheic / genetics. Point Mutation / genetics. Transcriptional Activation

  • MedlinePlus Health Information. consumer health - Skin Aging.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19298285.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3
  •  go-up   go-down


87. Cameron A, Rosendahl C, Tschandl P, Riedl E, Kittler H: Dermatoscopy of pigmented Bowen's disease. J Am Acad Dermatol; 2010 Apr;62(4):597-604
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatoscopy of pigmented Bowen's disease.
  • BACKGROUND: Pigmented Bowen's disease is not well characterized.
  • OBJECTIVE: To characterize the clinical and dermatoscopic appearance of pigmented Bowen's disease.
  • METHODS: We performed a retrospective analysis of 52 consecutive cases of pigmented Bowen's disease.
  • RESULTS: Of 951 histopathologically verified cases of Bowen's disease that underwent biopsy during the study period, 52 (5.5%) were pigmented.
  • Dermatoscopically pigmented Bowen's disease is typified by a pattern of dots and/or structureless zones.
  • CONCLUSIONS: Pigmented Bowen's disease has a characteristic dermatoscopic pattern.
  • Linear arrangement of brown and/or gray dots and/or coiled vessels is a specific clue to pigmented Bowen's disease.
  • [MeSH-major] Bowen's Disease / pathology. Dermoscopy. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Bowen's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20079953.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Perrem K, Lynch A, Conneely M, Wahlberg H, Murphy G, Leader M, Kay E: The higher incidence of squamous cell carcinoma in renal transplant recipients is associated with increased telomere lengths. Hum Pathol; 2007 Feb;38(2):351-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The higher incidence of squamous cell carcinoma in renal transplant recipients is associated with increased telomere lengths.
  • The incidence and aggressiveness of nonmelanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma (SCC), in immunocompromised renal transplant recipients (RTRs) is dramatically higher (up to 100-fold) compared with the normal population.
  • SCC lesions are also predominant in RTRs, in contrast to the normal population where basal cell carcinoma is more common.
  • The mechanisms underlying this phenomenon are unknown, but effective treatments for these skin tumors would have a significant impact upon morbidity in this group of patients.
  • The fundamental role of telomeres and telomerase in the development of most human cancers, including melanoma, is well established, but very few reports have assessed their function during the onset of nonmelanoma skin cancer.
  • To assess whether telomere maintenance plays any role in the increased incidence of SCC in renal transplant patients, we analyzed both the telomere lengths and telomerase expression levels in 44 SCCs and 22 Bowen's disease (BD) samples (carcinoma in situ) from RTRs and nontransplant patients.
  • Our findings provide statistically significant evidence that the telomeres are consistently longer in both BD RTR and SCC RTR lesions compared with their nontransplant counterparts.
  • We also show by immunohistochemistry that there is a trend toward higher telomerase levels in both the BD RTR and SCC RTR lesions, although this was not statistically significant.
  • Our data thus suggest that telomere lengthening may possibly be an early event in the development of SCC in renal transplant patients and demonstrate that telomere maintenance mechanisms should be further evaluated with respect to developing a future therapeutic strategy for these cancers.
  • [MeSH-major] Bowen's Disease / etiology. Carcinoma, Squamous Cell / etiology. Kidney Transplantation / adverse effects. Skin Neoplasms / etiology. Telomere / genetics
  • [MeSH-minor] Base Sequence. Cell Line. HeLa Cells. Humans. Immunocompromised Host. Immunohistochemistry. In Situ Hybridization, Fluorescence / methods. Telomerase / biosynthesis


89. Koch P, Stenzinger A, Viard M, Märker D, Mayser P, Nilles M, Schreiner D, Steger K, Wimmer M: The novel protein PTPIP51 is expressed in human keratinocyte carcinomas and their surrounding stroma. J Cell Mol Med; 2008 Oct;12(5B):2083-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The expression of PTPIP51 was investigated in keratinocyte carcinomas, that is human basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) as well as Bowen's disease (BD) and keratoacanthomas (KAs) on a transcriptional (mRNA) and translational (immunohistochemical) level.
  • METHODS: Formalin-fixed, paraffin-embedded sections of BCCs, SCCs, KAs and BD, respectively, were analysed by RT-PCR, as well as immunohistochemistry and subsequent fluorescence microscopy.
  • RESULTS: PTPIP51-expression was detected in BCCs and SCCs of the skin, as well as in KAs and BD.
  • Both types of keratinocyte carcinoma revealed a specific localization pattern of PTPIP51 in malignant keratinocytes.
  • Whereas PTPIP51-positive cells of BCC were found to form two cluster types with a different subcellular localization of the protein, i.e. cytoplasmic and nuclear or predominantly membranous, investigation of SCC revealed a meshwork-like appearance of PTPIP51-positive malignant keratinocytes, created by a mainly membranous localization.
  • BD and KA resembled the findings of PTPIP51-expression in SCC.
  • SCC and BCC showed a co-expression and partial co-localization of PTPIP51 with beta-catenin.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Keratinocytes / metabolism. Mitochondrial Proteins / metabolism. Protein Tyrosine Phosphatases / metabolism. Skin Neoplasms / metabolism. Stromal Cells / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19012732.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Mitochondrial Proteins; EC 3.1.3.48 / FAM82A2 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  • [Other-IDs] NLM/ PMC4506173
  •  go-up   go-down


90. Martínez S, del Boz J, Vera A, Sanz A, Crespo V: [Spindle-cell carcinoma in situ treated with 5% imiquimod]. Actas Dermosifiliogr; 2006 May;97(4):267-70
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spindle-cell carcinoma in situ treated with 5% imiquimod].
  • [Transliterated title] Carcinoma espinocelular in situ tratado con imiquimod al 5 %
  • We present the case of a 70-year-old woman with no personal history of interest who presented to her physician with a plaque in the right infraumbilical region whose largest diameter measured nine centimeters.
  • The clinical and histological diagnosis was Bowen's disease.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Bowen's Disease / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16801022.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ointments; 99011-02-6 / imiquimod
  • [Number-of-references] 22
  •  go-up   go-down


91. Lee JW, Hur J, Yeo KY, Yu HJ, Kim JS: A Case of Pigmented Bowen's Disease. Ann Dermatol; 2009 May;21(2):197-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Case of Pigmented Bowen's Disease.
  • Pigmented Bowen's disease is characterized by increased melanin pigment in the epidermis or papillary dermis, in addition to the typical findings of Bowen's disease.
  • This disorder has been infrequently reported and it represents less than 2% of all cases of Bowen's disease.
  • Thus far, there has been only 1 case of pigmented Bowen's disease on the umbilicus in the medical literature, and no such case has been reported in Korea.
  • Pigmented Bowen's disease develops on sun-exposed areas of the face and neck, as well as sun-unexposed areas like the trunk, extremities, perianal area and umbilcus.
  • From these findings, we diagnosed this lesion as pigmented Bowen's disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Actas Dermosifiliogr. 2008 Jun;99(5):419-20 [18501179.001]
  • [Cites] Arch Iran Med. 2007 Apr;10(2):255-7 [17367227.001]
  • [Cites] Australas J Dermatol. 2007 Feb;48(1):1-8; quiz 9-10 [17222293.001]
  • [Cites] Dermatol Surg. 2006 Dec;32(12):1522-5 [17199666.001]
  • [Cites] J Am Acad Dermatol. 2005 Jun;52(6):997-1002 [15928618.001]
  • [Cites] Br J Dermatol. 1998 Mar;138(3):515-8 [9580811.001]
  • [Cites] J Dermatol Surg Oncol. 1988 Jul;14(7):765-9 [3292613.001]
  • [Cites] J Dermatol Surg Oncol. 1986 Oct;12(10):1114-5 [3760318.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 1):541-4 [15056147.001]
  • [Cites] Dermatol Surg. 2001 Jul;27(7):673-4 [11442622.001]
  • [Cites] Br J Dermatol. 1999 Oct;141(4):633-41 [10583109.001]
  • (PMID = 20523786.001).
  • [ISSN] 2005-3894
  • [Journal-full-title] Annals of dermatology
  • [ISO-abbreviation] Ann Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2861209
  • [Keywords] NOTNLM ; Bowen's disease / Pigmented / Umbilicus
  •  go-up   go-down


92. Sharma R, Iyer M: Bowen's disease of the nipple in a young man with AIDS: a case report. Clin Breast Cancer; 2009 Feb;9(1):53-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowen's disease of the nipple in a young man with AIDS: a case report.
  • Bowen's disease, or squamous cell carcinoma in situ (SCCIS) of the skin, is a malignant neoplasm restricted to the epidermis, without evidence of dermal invasion.
  • It usually develops in sun-exposed area of skin, but other sites can also be affected.
  • Bowen's disease of the nipple is extremely rare and has thus far been reported only in women.
  • We present the case of Bowen's disease of the nipple in an HIV-positive male patient who presented with a scaly lesion on nipple for one year.
  • There was no evidence of invasive carcinoma.
  • To the best of our knowledge, this is the first reported case in the worldwide literature of Bowen's disease of the nipple in a young immunocompromised male patient.
  • [MeSH-major] Bowen's Disease / etiology. Breast Neoplasms, Male / pathology. HIV Infections / complications. Nipples / pathology


93. Shimizu A, Tamura A, Abe M, Motegi S, Nagai Y, Ishikawa O, Nakatani Y, Yamamoto Y, Uezato H, Hoshino H: Detection of human papillomavirus type 56 in Bowen's disease involving the nail matrix. Br J Dermatol; 2008 Jun;158(6):1273-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of human papillomavirus type 56 in Bowen's disease involving the nail matrix.
  • BACKGROUND: As Bowen's disease of the nail apparatus is quite rare, there have been only a few reports on the prevalence of human papillomavirus (HPV) infection in this condition.
  • OBJECTIVES: The purpose of this study was to clarify the association of HPV with this disease involving the nail apparatus.
  • METHODS: Five patients with Bowen's disease of the nail apparatus were investigated clinically, virologically and histologically.
  • Total DNAs extracted from excised skin lesions were analysed using polymerase chain reaction (PCR) for the presence of HPV DNA and the amplified products were subjected to DNA sequence analyses.
  • RESULTS: In three of five patients, HPV was detected by PCR amplification, and subsequent sequence analyses of the PCR products showed the sequences of HPV type 56.
  • CONCLUSIONS: HPV 56 may be involved in the carcinogenesis of Bowen's disease affecting the nail matrix with longitudinal pigmentation.
  • [MeSH-major] Bowen's Disease / pathology. DNA, Viral / isolation & purification. Nail Diseases / pathology. Papillomavirus Infections / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410409.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


94. Herat A, Shirato K, Damian DL, Finlayson R, Whitfeld M: Invasive squamous cell carcinoma arising in refractory perianal Bowen's disease in a HIV-positive individual. Australas J Dermatol; 2006 May;47(2):120-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive squamous cell carcinoma arising in refractory perianal Bowen's disease in a HIV-positive individual.
  • A 54-year-old HIV-positive homosexual man presented with erythematous and pigmented plaques on background erythema in the perianal region, histologically consistent with Bowen's disease.
  • Perianal Bowen's disease represents high-grade anal intraepithelial neoplasia, which is considered a precursor lesion of invasive anal squamous cell carcinoma.
  • He progressed to develop a poorly differentiated squamous cell carcinoma of the anus three and a half years after the Bowen's disease was diagnosed.
  • The squamous cell carcinoma was treated with combined chemoradiation.
  • [MeSH-major] Bowen's Disease / diagnosis. Carcinoma, Squamous Cell / diagnosis. HIV Infections. Neoplasm Recurrence, Local / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Anal Canal. Combined Modality Therapy. Diagnosis, Differential. Homosexuality, Male. Humans. Male. Middle Aged. Neoplasm Invasiveness


95. Alfaro-Rubio A, Nagore E, Serra C, Botella R, Sanmartín O, Requena C, Llombart B, Hueso L, Guillén C: [Perianal Bowen's disease treated with imiquimod]. Actas Dermosifiliogr; 2005 Sep;96(7):468-70
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Perianal Bowen's disease treated with imiquimod].
  • [Transliterated title] Enfermedad de Bowen perianal tratada con imiquimod.
  • Bowen's disease is a special form of squamous cell carcinoma in situ that usually develops in photoexposed areas of skin.
  • We contribute a new case of perianal Bowen's disease, which responded to treatment with imiquimod with no evidence of clinical recurrence after 3 years of follow up.
  • Imiquimod appears to be a therapeutic alternative for perianal Bowen's disease, which seems to have a particular tendency to recur in this location where surgery may also be complicated.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Bowen's Disease / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16476278.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


96. Alessi SS, Sanches JA, Oliveira WR, Messina MC, Pimentel ER, Festa Neto C: Treatment of cutaneous tumors with topical 5% imiquimod cream. Clinics (Sao Paulo); 2009;64(10):961-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Here, we present our experience in the treatment of 123 cutaneous tumors of various types, including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), Bowen's disease, erythroplasia of Queyrat, Paget's disease, and trichoepithelioma, with 5% imiquimod cream from 2003 to 2008 in the Cutaneous Oncology Group of the Dermatology Department of Hospital das Clinicas.
  • Patients were divided into two separate groups according to their diagnosis and comorbidities; these comorbidities included epidermodysplasia verruciformis, xeroderma pigmentosum, albinism, basal cell nevus syndrome, Brooke-Spiegler syndrome, HIV, chronic lymphocytic leukemia, B-cell lymphoma, and kidney transplantation.
  • These specific patients demonstrated cure rates of 83.5% for superficial BCC and 50% for Bowen's disease.
  • For these patients, the cure rates were 85.7% for superficial and nodular BCC, 88% for superficial BCC, 57% for Bowen's disease, 50% for nodular BCC, and 50% for aggressive BCC.
  • One SCC lesion demonstrated a complete response, and tumors caused by Paget's disease and erythroplasia of Queyrat presented a partial response.
  • Having a cutaneous comorbidity, high-risk tumors such as mixed aggressive BCC (sclerodermiform or micronodular), nodular BCC, or Bowen's disease, and presenting no local reaction to imiquimod were considered as risk factors for a worse prognosis.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1999 Dec;41(6):1002-7 [10570388.001]
  • [Cites] J Am Acad Dermatol. 2001 May;44(5):807-13 [11312429.001]
  • [Cites] Dermatol Surg. 2002 May;28(5):427-9 [12030878.001]
  • [Cites] Arch Dermatol. 2002 Sep;138(9):1165-71 [12224977.001]
  • [Cites] J Dermatolog Treat. 2002 Sep;13(3):123-7 [12227875.001]
  • [Cites] J Am Acad Dermatol. 2002 Oct;47(4 Suppl):S240-8 [12271286.001]
  • [Cites] J Drugs Dermatol. 2008 May;7(5):447-51 [18505136.001]
  • [Cites] Dermatol Surg. 2003 Oct;29(10):1027-34 [12974699.001]
  • [Cites] Dermatol Surg. 2003 Dec;29(12):1181-6 [14725659.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]
  • [Cites] Br J Dermatol. 2005 May;152(5):939-47 [15888150.001]
  • [Cites] Eur J Dermatol. 2005 Sep-Oct;15(5):374-81 [16172048.001]
  • [Cites] J Drugs Dermatol. 2007 May;6(5):507-13 [17679185.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1227-36 [12452875.001]
  • (PMID = 19841702.001).
  • [ISSN] 1980-5322
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  • [Other-IDs] NLM/ PMC2763070
  • [Keywords] NOTNLM ; Basal cell carcinoma / Imiquimod / Immunomodulator / Immunotherapy / Non-melanoma skin cancer
  •  go-up   go-down


97. Pua VS, Huilgol S, Hill D: Evaluation of the treatment of non-melanoma skin cancers by surgical excision. Australas J Dermatol; 2009 Aug;50(3):171-5
MedlinePlus Health Information. consumer health - Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the treatment of non-melanoma skin cancers by surgical excision.
  • A retrospective study of all non-melanoma skin cancers excised by two dermatologists at a private practice in 2004 (excluding Mohs microscopic surgery cases) was conducted.
  • For basal cell cancers, the incomplete excision rate was 1.54% (5/324) and for squamous cell cancers including Bowen's disease the incomplete excision rate was 3.9% (5/129).
  • [MeSH-major] Neoplasm, Residual / pathology. Skin Neoplasms / pathology. Skin Neoplasms / surgery. Surgical Procedures, Operative / methods
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Biopsy, Needle. Carcinoma, Basal Cell / mortality. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Cohort Studies. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. Reoperation. Retrospective Studies. Risk Assessment. Sex Factors. South Australia. Survival Analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19659977.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


98. Tierney E, Barker A, Ahdout J, Hanke CW, Moy RL, Kouba DJ: Photodynamic therapy for the treatment of cutaneous neoplasia, inflammatory disorders, and photoaging. Dermatol Surg; 2009 May;35(5):725-46
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Photodynamic therapy (PDT) has demonstrated high efficacy, minimal side effects, and improved cosmetic outcome when used for the treatment of actinic keratoses (AK), basal cell carcinoma (BCC), squamous cell carcinoma, and photoaging.
  • For superficial BCC, initial clearance rates were 76% to 97%, and for Bowen's disease, initial clearance rates ranged from 72% to 94% overall.
  • Although the theory behind the use of chemical photosensitizers and ultraviolet light to treat a wide variety of skin disorders is straightforward, the practical application of this technology is evolving.
  • [MeSH-major] Dermatitis / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Skin Aging / drug effects. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Aging.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19309338.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  • [Number-of-references] 98
  •  go-up   go-down


99. Elamin I, Zecević RD, Vojvodić D, Medenica L, Pavlović MD: Cytokine concentrations in basal cell carcinomas of different histological types and localization. Acta Dermatovenerol Alp Pannonica Adriat; 2008 Jun;17(2):55-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine concentrations in basal cell carcinomas of different histological types and localization.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common malignant skin tumor.
  • OBJECTIVE: We were interested in comparing cytokine levels in BCC and cutaneous squamous cell tumors with BCC of different localization and histological subtypes.
  • MATERIAL AND METHODS: Explants from freshly excised BCC from 18 patients, and cutaneous squamous cell tumors (solar keratoses and Bowen's disease) from 9 patients were cultivated for 24 h.
  • RESULTS: Tissue explants of BCC contained significantly higher concentrations of IL-1beta, IL-4, IL-5, and IL-6 compared to those of squamous cell tumors.
  • [MeSH-major] Carcinoma, Basal Cell / chemistry. Cytokines / analysis. Skin Neoplasms / chemistry
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / chemistry. Female. Humans. Interleukin-4 / analysis. Interleukin-5 / analysis. Male. Tumor Necrosis Factor-alpha / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18709290.001).
  • [ISSN] 1318-4458
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovenia
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-5; 0 / Tumor Necrosis Factor-alpha; 207137-56-2 / Interleukin-4
  •  go-up   go-down


100. Mistrangelo M, Bellò M, Mobiglia A, Beltramo G, Cassoni P, Milanesi E, Cornaglia S, Pelosi E, Giunta F, Sandrucci S, Mussa A: Feasibility of the sentinel node biopsy in anal cancer. Q J Nucl Med Mol Imaging; 2009 Feb;53(1):3-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Histology revealed 23 squamous carcinomas, 10 basaloid carcinomas, 1 squamous carcinoma with basaloid areas and 1 spinocellular epithelioma associated with areas of Bowen's disease.
  • Disease stage was T1 in 5 patients, T2 in 18, T3 in 11 and T4 in 1 patient.
  • CONCLUSIONS: Given the correlation between prognosis and node involvement, sentinel node biopsy can be considered a simple method for adequate pretreatment staging of anal carcinoma.
  • [MeSH-major] Anus Neoplasms / diagnosis. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Follow-Up Studies. Humans. Inguinal Canal / pathology. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Neoplasm Staging. Recurrence

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18337684.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down






Advertisement